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ABSTRACT
The efficacy of a novel plasmid delivery system was assessed for long-term expression of
gonadotropin releasing hormone (GnRH) and growth hormone releasing hormone (GHRH) in
horses and goats.  The efficacy of the technology was demonstrated using 3 novel plasmids:
pSEAP [expressing secreted embryonic alkaline phosphatase (SEAP)], pGHRH (expressing
GHRH), and pGnRH (expressing GnRH).  Geldings were electroporated with a reporter plasmid
expressing SEAP in 3 muscle sites.  Expression of SEAP, measured from jugular plasma
samples, indicated muscle specificity for uptake and expression of the plasmid.  Concentrations
of SEAP were greatest (P < 0.05) after pectoralis injection, which was chosen as the site for
electroporation in subsequent studies.   In a second experiment, stallions were electroporated
with pGHRH or pSEAP to evaluate the effect of long-term GHRH treatment on the growth
hormone (GH) axis and testicular function.  Stallions treated with pGHRH had increased (P <
0.05) plasma concentrations of IGF-I, increased (P < 0.05) volume of accessory sex gland fluid,
and increased (P < 0.05) number of normal spermatozoa in the ejaculate relative to controls.  In
the third experiment, stallions were electroporated with pGnRH or pSEAP to test the effects of
GnRH on the reproductive axis.  Treatment with pGnRH increased (P < 0.05) plasma
testosterone concentrations to d 56 and increased (P < 0.01) the LH response to GnRH on d 21,
but did not alter (P > 0.1) seminal characteristics evaluated after 36 d of treatment.  In a final
experiment, goat does were treated with pGnRH or pSEAP to assess the effects of GnRH
treatment on the reproductive axis during seasonal anestrus.  Plasma concentrations of LH and
FSH were not affected (P > 0.1) by treatment through d 56.  Plasma progesterone measurements
indicated that ovulation did not occur in does treated with pGnRH or pSEAP.  Does treated with
pSEAP had increased (P < 0.05) plasma SEAP concentrations.  In conclusion, electroporatic
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plasmid delivery of peptide hormones may serve as an effective technique for expression of
protein hormones in the horse and goat.  
1
INTRODUCTION
Traditionally, hormone therapy with protein or peptide hormones, agonists, and
antagonists that are short-lived in vivo required frequent bolus injections or depot delivery to
elicit long-term effects on physiologic systems.  Recently, the ability to transfect DNA into an
adult mammal has overcome the barriers of impracticality and economic infeasibility associated
with protein hormone therapy.  Mammalian plasmid delivery has evolved over the past decade
into a safe approach for delivery of DNA and the gene product in vivo.  This technique is
currently being optimized for application as a minimally invasive intramuscular plasmid delivery
system for mammals (Draghia-Alki and Smith, 2003).  Electroporatic delivery of plasmids with
promoters optimized for mammalian muscle tissue has resulted in successfully high expression
levels of protein in mice (Lucas and Heller, 2001; Lesbordes et al., 2002), rats (Terada et al.,
2001; Yasui et al., 2001), dogs (Fewell et al., 2001; Draghia-Akli et al., 2003a), and pigs
(Draghia-Akli et al., 2003b; Draghia-Akli and Fiorotto, 2004).  
In various species, GH treatment has been beneficial on numerous physiologic systems. 
In the normal horse, GH has been evaluated for its effects on the cardiovascular system
(McKeever and Malinowski, 1997), the musculoskeletal and immune system (Malinowski et al.,
1997; Smith et al., 1999), and the reproductive axis (Cochran et al., 1999; Aurich et al., 2003;
Storer et al., 2005).  Growth hormone treatment has resulted in increased granulocyte number
and musculation in aged mares (Malinowski et al., 1997), increased number of small follicles on
the ovaries (Cochran et al., 1999), and increased accessory sex gland function in stallions (Storer
et al., 2005).  Researchers have yet to examine the effects of chronic GH treatment on many
physiologic systems in the horse. 
Treatment with GnRH, the hypothalamic peptide regulating pituitary LH and FSH
secretion, and its analogs has shown promise for inducing reproductive recrudescence during
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deep anestrus in mares (Johnson, 1986b, 1987; Turner and Irvine, 1991).  Problems have arisen
with these treatments due to an inability to stimulate physiological GnRH secretion.  Native
GnRH is short-lived in circulation and requires frequent administration or continuous infusion to
mimic physiologic secretion (Johnson, 1986b).  Generation of a plasmid expressing GnRH
would allow for investigation of the effects of long-term GnRH treatment on various
physiological mechanisms including seasonal reproduction.
The following series of experiments was designed to study the potential of plasmid
delivery systems as a replacement for repeated or depot-like injections in horses and goats.  After
an initial experiment to determine the best muscle group for injection and electroporation in
horses, two other systems were studied in which potential applications could have positive
physiologic and hence commercial impact: 1) GHRH production and secretion for the long-term
enhancement of GH secretion in horses, and 2) GnRH production and secretion for the possible




Mammalian Plasmid Delivery Systems
Plasmid delivery is becoming an alternative therapy to routine peptide hormone
injections.  Traditionally, hormone therapy has been limited to administration of hormones,
agonists, and antagonists that are short-lived in vivo and require frequent bolus or depot delivery
to elicit desired, long-term effects on physiologic systems.  The ability to transfect DNA into an
adult mammal has overcome the barriers of impracticality associated with protein hormone
therapy.  Plasmid gene transfer is ideal when prolonged low-level expression is desirable.  In
many instances, protein hormone therapy can be inefficient and labor intensive.  This is due in
part to the cost, availability, and pharmacokinetics of many protein preparations.  Combining
new plasmid delivery technologies with the elucidation of genetic information for domestic
mammals could expand the use of this technique in future therapies.  Many factors relating to the
efficacy of electroporatic delivery must be determined for maximum utilization of the
technology.  Particularly, selection of species-specific delivery sites, determination of promoters
optimized for specific tissues, and production of functional genetic inserts must be established.  
Plasmids are small circular molecules of double stranded DNA attained from bacterial
cells (Alberts et al., 2002).  Plasmids are widely used as cloning vectors due to their ability to
replicate in bacteria (Alberts et al., 2002).  Modifications can be made to plasmids by restriction
nuclease digestion and ligation to accommodate genetic inserts including mammalian genes
(Alberts et al., 2002).  Once a gene is inserted into the plasmid, the gene becomes stable and
reproducible (Wolff et al., 1990; Acsadi et al., 1991).  The incorporated DNA can then be
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grown-up in bacterial culture, purified, and transfected to mammalian tissue in vitro or in vivo
for expression of encoded peptides (Alberts et al., 2002).  
Mammalian plasmid delivery is the process of transferring plasmid DNA into mammals
for in vivo genetic expression.  The process has evolved over the past decade into a safe
approach for delivery of DNA in vivo (Draghia-Alki and Smith, 2003).  Other approaches to in
vivo gene transfer are being studied with limited success.  Viral vectors (Baker et al., 2005; 
Kapturczak et al., 2005) and transposable vectors (Largaespada, 2003) are two alternative means
of gene transfer.  These techniques are fairly effective, but generally result in poor efficiency,
poor tissue selectivity, or immunogenicity (Largaespada, 2003; Baker et al., 2005; Kapturczak et
al., 2005).  Plasmids are fairly simple to construct, relatively inexpensive, and of low risk when
compared to viral vectors and transposable vectors (Frederickson et al., 2003).  Plasmids do not
become incorporated into the cell's genomic DNA.  Consequently, transgene expression from
plasmids is dependent on the turnover rate of the transfected cell type (Lechardeur et al., 1999). 
This results in a restriction of expression to the site of incorporation. Therefore, the expression is
confined, which makes plasmid expression both reversible and safe. 
Previous short-comings of plasmid gene transfer were low expression levels brought
about by diminished cellular incorporation due to cell death and minimal cellular uptake during
transfection (Danko and Wolff, 1994; Tsurumi et al., 1996).  New technologies have made it
possible to increase DNA incorporation into mature mammalian cells.  One of the most
promising of these technologies is electroporatic plasmid delivery (Draghia-Akli et al., 2002;
Draghia-Akli and Fiorotto, 2004; Khan et al., 2005).  Electroporation, also described as
electropermeabilization or electrokinetic enhancement, is the process of exposing the transfected
tissue to a brief electric pulse.  This results in a transient permeability of the lipophilic cell
membrane to hydrophilic molecules (Smith and Nordstrom, 2000).  Electroporation has been
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used extensively for gene transfer, DNA vaccination, and drug delivery in vivo and in vitro
(Draghia-Alki and Smith, 2003).  Electroporation requires application of conductive electrodes
to the transfected tissue.  Various electrodes have been studied.  These include conductive
clamps, tweezers, paddles, and needles.  The electrode design is dependent on the nature of the
target tissue (Gilbert et al., 1997).  It is essential to have the electrical current applied as close to
the injected DNA solution as possible.  For this reason, specific electrodes are preferred for
different tissues to facilitate maximal DNA incorporation.  
Previously, the use of electroporation was limited due to damage of affected cells and
degradation of the plasmid (Fewell et al., 2001).  Electric field intensity, length of pulse, and
design of electrodes have been factors contributing to the adverse effects of electroporation
(Bureau et al., 2000).  Innovations on the technology were reported by Draghia-Alki and
colleagues (2002).  With their technique, minimal injection site pathology was observed when
compared to traditional electroporation (Draghia-Akli et al., 2003b).  An electrode needle array
delivering a constant current has been most effective at minimizing cellular degradation due to
heat produced during electroporation.  Also, the addition of polymers to the DNA formulation
was shown to improve cellular uptake.  Polyvinylpyrrolidone (PVP) and poly-L-glutamate
(PLG) are believed to aid in mending the cellular membrane subsequent to electroporation
(Draghia-Akli et al., 2002).  
Some variation in plasmid production has been attributed to the site of electroporation
due to differences in tissue and cell variation (Draghia-Akli et al., 2003b).  Long-lived cells seem
to respond best to electroporation due to cellular recovery and longevity of expression.  Large
cell types have been found to be more resilient to the effects of electroporation (Neumann et al.,
1999).  Muscle cells have been the focus of electroporatic delivery for these reasons.  Maximized
plasmid uptake and expression are very often muscle specific and may vary from species to 
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species (Draghia-Alki et al., 2002; 2003a,b).  In pigs transfected into the longissimus dorsi and
the semitendinosus muscles, the semitendinosus muscle gave the greatest expression
(Draghia-Akli et al., 2003b).  It was concluded that differences in cellular uptake of plasmid
DNA could be determined by muscle fiber types, vasculature of the affected muscle, and
subsequent muscle activity.  
Although plasmid expression is limited by the life of the transfected cell, in vivo muscle
cell transfection has produced expression up to 100 d in duration.  In some instances, effects of
transfection have been transferred to the offspring (Khan et al., 2002, 2003a).  Khan and
colleagues (2003a) reported increased weight gain, feed efficiency, and number of GH staining
cells in the pituitaries of piglets farrowed by sows treated with a plasmid expressing GHRH. 
Considering the episomal nature of muscle-specific plasmid transfection, Khan and colleagues
hypothesized that GHRH passing through the placental barrier affected the GHRH/GH/IGF-I
axis of the offspring, increasing the number of somatotropes and GH secretion postnatally.  
Mutated genes and genes from different species can be expressed through plasmid
delivery.  Studies conducted with electroporation of plasmids encoding a manipulated porcine
GHRH gene have revealed that mutated porcine genes will function in dogs (Draghia-Akli et al.,
2003a) and cattle (Brown et al., 2004).  These results confirm the efficacy of plasmid delivery
for interspecies gene transfer.  Plasmid promoters dramatically affect the transcription of an
encoded gene and can be optimized to be tissue specific and exceed physiologic promoter
expression levels (Li et al., 1999).  Electroporatic delivery of plasmids with promoters optimized
for mammalian muscle tissue have successfully expressed high levels of protein in mice (Lucas
and Heller, 2001; Lesbordes et al., 2002), rats (Terada et al., 2001; Yasui et al., 2001), dogs
(Fewell et al., 2001; Draghia-Akli et al., 2003a), and pigs (Draghia-Akli et al., 2003b;
Draghia-Akli and Fiorotto, 2004).  For instance, the promoter SPc5-12 is a synthetic promoter
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developed to produce high levels of protein when delivered into mammalian muscle tissue (Li et
al., 1999).  The promoter is capable of driving transcription in mice, pigs, and dogs with no
indication of bias among species (Draghia-Akli et al., 2002).  
Growth Hormone in the Horse
Growth hormone is a 191 amino acid protein secreted by the somatotropes of the pars
distalis (Hadley, 2000). It was named for its ability to stimulate growth in short statured
individuals.  Although GH was first discovered for its growth enhancing characteristics, it has
since been found to play a role in numerous physiologic systems.  Growth hormone stimulates
amino acid anabolism, fatty acid mobilization, and collagen deposition to list a few.  Growth
hormone also stimulates the release of IGF-I from the liver, expanding its influence on
mammalian physiology.  The two hormones are usually studied in unison due to their tightly
linked participation in the GH axis feed-back loop (Hadley, 2000).  
In the horse, GH is produced in two distinct cell types in the pars distalis: GH secreting
somatotropes and cells producing both prolactin and growth hormone (Rahmanian et al., 1997). 
Equine GH secretion, determined by radioimmunoassay of jugular plasma samples, is episodic,
with pulses superimposed upon basal secretion (Thompson et al., 1992; Stewart et al., 1993).  In
the foal, plasma concentrations of GH are relatively low at birth.  Shortly thereafter,
concentrations of GH rise sharply before descending to basal levels (Stewart et al., 1993).
Another rise in GH concentrations occurs at the onset of puberty (Fortier et al., 2005).  In
adult horses, plasma GH concentrations are greater in stallions than mares (Thompson et al.,
1994).  
Treatment with GH has revealed many physiologic roles of the hormone.  Foals treated
with GH develop increased internal organ weights; organs affected by GH treatment include the
adrenal gland, kidney, liver, pancreas, spleen, and heart (Kulinski et al., 2002).  This indicates a
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role of GH or IGF-I on the development of these internal organs.  The effects on general health
of this  pharmacologically-induced hypertrophy of these organs in the horse are unknown, but
aerobic capacity and exercise performance is not improved by short-term GH treatment
(McKeever et al., 1998; Gerard et al., 2002).  Conversely, body weight was not changed in
GH-treated developing foals as has been seen in other developing animals (Capshaw et al.,
2001).  In addition, GH treatment was not effective at altering the anatomical assessments of 
height at withers, length of body, widths of chest and rump, heart girth, length of head, front or
rear cannon lengths, front or rear cannon circumferences, gaskin circumference, or skin
thickness (Capshaw et al., 2001). 
Growth hormone is involved in the metabolic processes of the horse, and treatment with
exogenous GH induces hyperglycemia, hyperinsulinemia, insulin insensitivity, mobilization of
fatty acids and decreased urea-nitrogen concentrations (Smith et al., 1999).  Increased muscle
anabolism and decreased fat deposition are affected by GH as indicated by increased loin-eye
area in foals (Kulinski et al., 2002) and increased musculation in aged mares (Malinowski et al.,
1997).  Induced protein deficiency increases GH secretion, whereas energy restriction has little
effect on GH secretion and decreases IGF-I secretion (Sticker et al., 1995b).  
Growth hormone has also been evaluated for its effects on the immune system and
reproductive axis.  Reproductive effects attributed to GH include increased number of small
follicles on the ovaries of the mare (Cochran et al., 1999) and increased testicular (Aurich et al.,
1999) and accessory sex gland function (Storer et al., 2005) in the stallion.  Growth hormone has
also been found to stimulate the immune response as is indicated by increased granulocyte
number (Malinowski et al., 1997; Guirnalda et al., 2001).
The exact physiologic mechanisms that regulate equine GH synthesis and secretion are
still being elucidated.  Two hypothalamic neuropeptides are thought to predominately control
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GH secretion: somatostatin negatively influences basal GH plasma concentrations, and GHRH
stimulates episodic GH secretion (Hadley, 2000).  These two hormones, acting in concert, are
allegedly responsible for maintaining GH homeostasis (Hadley, 2000).  
In the horse, plasma GH concentrations can be increased by various secretagogues
(Sticker et al., 2001), feeding (Christensen et al., 1997; Nadal et al., 1997), and exercise
(Thompson et al., 1992, 1994; Sticker et al., 1995a).  The possible mechanisms responsible for
the GH responses to these stimuli may involve somatostatin, GHRH, or both.  Pharmacological
doses of GHRH are known to dramatically increase GH secretion.  Plasma GH concentrations in
response to GHRH decrease with consecutive injections and are variable in amplitude
(Thompson et al., 1994).  Constant infusion of GHRH has not been evaluated in the horse.  In
humans, constant infusion of GHRH over 24 h does not affect basal plasma GH concentrations,
but pulses are augmented and IGF-I concentrations are increased (Vance et al., 1985).  This
indicates that constant input of GHRH may work to increase intracellular production of GH
rather than increase its secretion.  From studies on active immunization against GHRH or
somatostatin in sheep, it has been shown that many of the secretagogue-induced increases in GH
are regulated more by increases in GHRH than by decreases in somatostatin (Magnan et al.,
1995).  Similar results have been demonstrated in the pig (Farmer et al., 1991).  This similarity
within species may indicate that the mode of regulation by GHRH and somatostatin would be
similar for the horse.  These data also reveal that the variability and the lack of understanding
associated with the GH axis is consistent among species.  
Other factors have been shown to affect GH secretion.  Infusion of aspartic acid, glutamic
acid, or n-methyl aspartate increases GH in the horse (Sticker et al., 2001).  Thyrotropin
releasing hormone administration inhibits pharmacological and exercise-induced GH secretion in
the horse (Pruett et al., 2003).  The exact mechanisms of action for many of these factors are not
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well understood.  The current dogma is that these factors directly or indirectly alter the
opposition of GHRH and somatostatin, resulting in a pulsatile release of GH.  
Effects of Growth Hormone on Equine Reproduction
Growth hormone and IGF-I have been found to affect reproduction in most domestic
species.  Growth hormone deficiency in humans (Kulin et al., 1981) and cattle (Cohick et al.,
1996) is associated with delayed puberty, and treatment of the deficiency can normalize the
retarded maturation.  This is corroborated by evidence in male mice that indicates prepubertal
differentiation of Leydig and Sertoli cells is GH dependent (Hochereau-de Reviers et al., 1987). 
Growth hormone and IGF-I receptors have been identified in the Leydig and Sertoli cells of rat
testes (Smith et al., 1987).  Furthermore, GH has been found to increase testosterone secretion
and spermatogenesis in humans (Kulin et al., 1981) and mice (Chatelain et al., 1991).  The
effects of GH on reproduction in these species seem to be directly on the gonads, influencing
steroid and gamete production directly or indirectly. The indirect influence of GH might be to
increase gonadotropin receptors at the level of the gonad, thereby increasing the efficacy of
circulating gonadotropins.  
As in other species, GH treatment affects equine reproduction.  Stallions treated with GH
have increased testosterone secretion in response to human chorionic gonadotropin (Aurich et
al., 2003) and increased accessory sex gland function (Storer et al., 2005).  Similarly, mares
treated with GH develop increased number of small follicles on the ovaries (Cochran et al.,
1999).  These effects of GH and IGF-I on the equine gonads are similar to those seen in other
species.  In the horse and other domestic species, blood levels of GH increase at the time of
puberty (Mauras et al., 1996; Fortier et al., 2005).  This is indicative of an influence of GH or
IGF-I on the maturation of the gonads and on gametogenesis.  This may explain the presence of
GH receptors on the testis (Spiteri-Grech and Nieschlag, 1992).
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Based on other relationships between equine and nonequine species, IGF-I may also be
involved in spermatogenesis.  Specific IGF-I receptors have been found on Sertoli cells and
Leydig cells of rats (Moore et al., 1993) and humans (Neuvians et al., 2005).  Despite these data,
the involvement of GH in equine reproduction remains unclear.  Hess and Roser (2005) reported
conflicting results that GH, IGF-I, or both did not alter Leydig cell testosterone response to
equine LH in vitro compared to GH and IGF-I free media.  Also, daily treatment with
recombinant equine GH for 21 d did not improve the gonadotropin response to a physiologic
dose of GnRH, testosterone response to equine LH injection, or sperm morphology (Storer et al.,
2005).  Further evaluation of the involvement of GH in equine reproduction is needed to clarify
these issues.
Gonadotropin Releasing Hormone in the Horse
There are many challenges in equine reproduction that need further study.  These include
inducing fertile estrus during the winter, pinpointing ovulation, regulating reproductive behavior,
and improving seminal quality.  Manipulation of GnRH could help elucidate many of the
physiologic mechanisms regulating these factors.  Investigators have shown that native GnRH
and GnRH analogs are promising treatments for inducing cyclicity during anestrus, inducing
ovulation, and altering libido.  Appropriate GnRH therapies able to accomplish desirable
outcomes in these areas have yet to be established.  
As reviewed by Hadley (2000), GnRH is a 10 amino acid neuropeptide produced in the
hypothalamus of most mammals.  Neurons secreting GnRH are directed to the
hypophyseal-portal system feeding the pars tuberalis.  The primary function of GnRH is the
regulation of gonadotropin secretion from the gonadotropes of the adenohypophysis. 
Stimulation of the gonadotropes has been determined to differentially regulate LH and FSH
12
secretions that in turn predominately regulate gonadal steroid synthesis and gamete production. 
Negative feed-back from gonadal steroids regulates secretion of GnRH and the gonadotropins.
In the horse, GnRH neurons are diffusely distributed throughout the mediobasal
hypothalamus (Melrose et al., 1994).  The short half-life of GnRH in peripheral blood, combined
with the large degree of dilution in the venous drainage, make jugular concentrations of GnRH
undetectable with routine radioimmunoassay.  Measurements of GnRH secretion have been
collected through cannulation of the hypothalamo-hypophyseal portal vessel (Alexander and
Irvine, 1987; Irvine and Alexander, 1988) and push-pull perfusion of the medial basal
hypothalamus (Sharp and Grubaugh, 1987).  These data indicate that secretion of GnRH is
pulsatile in nature, and generally pulses in GnRH precede pulses in LH and FSH, although peaks
in GnRH secretion are more closely related to surges in LH than in FSH.  The effects of GnRH
on the pituitary have also been studied through disruption of the communication between the
hypothalamus and pituitary (pituitary stalk-sectioned; Porter et al., 1997a).  In pituitary
stalk-sectioned pony mares, pulsatile GnRH administration is necessary to reestablish basal LH
secretion.  
Release of GnRH is believed to be regulated by environmental stimuli in seasonal
animals.  The horse is a seasonal breeder, with greatest reproductive activity during the long
days of spring and summer.  Hypothalamic GnRH content and GnRH secretion are greatest
during the summer.  Hart and colleagues (1984) reported that content of GnRH in the
hypothalamus of mares varied with season and was lowest during midwinter. Conversely, they
found no effect of season on number of receptors for GnRH in the pituitary. In another study,
Sharp and Grubaugh (1987) reported differences in GnRH concentrations from perfused
hypothalami between seasonally anestrous and cyclic mares.  These data indicate that
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secretion patterns and intracellular stores of GnRH are regulated by season, while the number of
GnRH receptors in the pituitary remains fairly constant through out the year.  
Many of the physiologic roles of GnRH have been elucidated by experiments based on
active or passive immunization against GnRH.  In stallions, immunoneutralization of GnRH 
resulted in decreased sperm number, decreased gonadotropin production, decreased gonadal
steroid production, and decreased libido (Malmgren et al., 2001; Turkstra et al., 2005). 
Similarly, in the mare, GnRH immunization results in decreased gonadotropin production,
decreased steroid production, and decreased follicular growth on the ovaries (Garza et al., 1986;
Rabb et al., 1990; Imboden et al., 2006).  Prolonged treatment with potent analogs of GnRH has
produced similar results (Johnson et al., 2002; Johnson et al., 2003).  These data reinforce the
concept that GnRH is crucial for equine reproduction.   
Problems have arisen in attempting to manipulate reproductive aspects of the horse with
GnRH due to an inability to augment physiologic GnRH secretion for extended periods of time. 
Native GnRH is short-lived in circulation and requires frequent administration or continuous
infusion to exert long-term effects on reproduction.  Conversely, potent agonists of GnRH
overwhelm the hypothalamic-pituitary axis and have been associated with down-regulation of
gonadotropins (Johnson et al., 2002, 2003).  
Extensive research involving GnRH and its analogs has been conducted in seasonally
anestrous mares with the goal of inducing ovulation.  During seasonal anestrus, daily
administration of GnRH stimulates LH and FSH secretion temporarily but does not increase
basal plasma gonadotropin levels or induce significant effects on reproduction (Gentry et al.,
2002).  In addition, the gonadotropin response to daily injections gradually increases over time,
indicating a possible GnRH-induced stimulation of intracellular production but inefficacy at
increasing basal secretion of gonadotropins (Gentry et al., 2002).  To cause an increase in basal
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gonadotropin levels, hourly treatment with GnRH, similar to natural secretion, may be the most
effective mode of administration, but may not be necessary.  Imitating the natural pulsatility of
physiologic GnRH secretion has been the most effective method for inducing ovulation in
anestrus and transitional mares resulting in ovulation rates of 50 to 80% (Johnson, 1986a, 1987;
Johnson et al., 1988; Turner and Irvine, 1991).  Johnson (1986a, 1987) reported that hourly
injections of GnRH administered to anestrous mares resulted in increased basal LH secretion and
ovulation followed by development of a functional corpus luteum (Johnson, 1986a).  This
method, however, is inadequate for field use due to the excessive labor input.
Alternative methods of GnRH administration have been studied to facilitate on-farm
application.  To date, attempts at more physiologic GnRH therapies have involved minipumps,
slow-releasing compounds, and analogs.  In some studies, these treatments appear to be fairly
effective at inducing ovulation in anestrous mares.  For instance, treatment with the GnRH
analog buserelin was reported to hasten the first ovulation of the year in seasonally anestrous
mares (Harrison et al., 1990; Mumford et al., 1994).  Similar studies involving slow-releasing
subcutaneous implants of less potent GnRH analogs and infusion of GnRH have been marginally
effective at inducing ovulation during late anestrus and transition, but of the mares that begin to
show significant follicular activity, many return to an anestrous state or fail to ovulate (Allen et
al., 1987; Hyland et al., 1987; Harrison et al., 1990; Fitzgerald et al., 1993).  These studies
indicated that the responses to these alternative methods are variable and inconsistent.  In all
instances, it is implied that a more physiologic regulation of gonadotropin secretion is dependent
on the pulsatile secretion pattern of GnRH, which further establishes that pulsatile administration
of GnRH is needed to restore physiologic levels of LH and FSH and subsequent ovulation
(Porter et al., 1997a).  Pulsatile infusion of GnRH results in a greater increase in plasma
gonadotropin concentrations than continuous infusion (Becker and Johnson, 1992).  This
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criterion for inducing gonadotropin secretion with GnRH makes GnRH therapy difficult to
implement.  
Currently, potent GnRH agonists, GnRH antagonists, and GnRH vaccines are being
studied as treatments for inhibiting reproductive function and behavior in mature horses.  Potent
agonists of GnRH have been effective for short-term inhibition of gonadotropin secretion
(Johnson et al., 2002).  However, the horse has proved quite resilient to the long-term
down-regulation seen in other species.  Due to the short-lived deprivation of gonadotropins,
these agonists have little efficacy on altering behavior.  Vaccines against GnRH have proven to
be adequate for decreasing gonadotropin and steroid production but are prone to injection site
necrosis and are variable in efficacy (Thompson, 2000; Stout and Colenbrander, 2004). 
Antagonists of GnRH have been effective in other species, but studies in horses are limited due
to the expense of treatment (Stout and Colenbrander, 2004).  The GnRH antagonist Cetrorelix
inhibits both LH and FSH secretion in vitro, but the antagonist has limited efficacy in vivo
(Evans et al., 2002).  
In the stallion, pulsatile administration of GnRH manifests a transient rise in plasma LH
and testosterone concentrations that is ineffective at altering testicular size or sperm output, but
constant infusion of similar low levels of GnRH is not effective at altering reproduction (Blue et
al., 1991).  Potent agonists induce an initial sharp increase in gonadotropins followed by a
short-lived suppression, similar to the pattern displayed in mares, with no noticeable effects on
libido and sperm output (Boyle et al., 1991; Johnson et al., 2003).  These data indicate that the
stallion is similar to the mare, in that pulsatile administration of native GnRH is most efficient at
inducing desirable outcomes on reproduction.  
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Gonadotropin Releasing Hormone in the Goat Doe
Research regarding caprine reproduction is limited due to the lack of goat production in
developed countries.  This has detracted from the understanding of caprine reproductive
physiology.  Many of the physiological roles of GnRH in caprine reproduction have yet to be
elucidated.  Much of the knowledge concerning caprine reproduction has been derived from
research in sheep.  This is due to the fact that the goat, like the sheep, is seasonally polyestrous,
with most breeding activity occurring during the fall and winter.  Current knowledge of caprine
reproduction has begun to broaden with increasing interest in research endeavors brought on by
an increase in desire for goat products in developed countries.  Still, many factors affecting
caprine reproduction have yet to be determined.  Treatment with GnRH offers opportunities for
improving caprine reproduction.  
The caprine estrous cycle is generally 21 d in length, with standing estrus displayed in
the final 24 to 48 h (Rubianes and Menchaca, 2003).  Similar to other farm species, the
reproductive cycle consists of 2 main phases.  Progesterone predominates during the luteal
phase, generally15 d long (de Castro et al., 1999).  Elevated levels of FSH during the luteal
phase give rise to the development of follicular waves.  Goats display a wave-like pattern of
follicular growth emerging every 5 to 7 d, resulting in an average of 4 waves over the 21 d cycle
(Ginther and Kot, 1994).  In the follicular phase, estrogen rises before ovulation in association
with the emergence of a dominant, ovulatory follicle.  Estrogen exerts a biphasic effect on LH
secretion by acting at the level of the hypothalamus and pituitary in a manner similar to that
described for the cow.  The initial effect of estrogen is to suppress LH secretion before
stimulating the final ovulatory surge (Sakurai et al., 1995).  
Secretion of GnRH from the hypothalamus is believed to be the primary influence for
changes occurring during the estrous cycle.  For example, progesterone implantation for an
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extended period results in a surge in gonadotropins upon removal.  This is blocked by
immunization against GnRH and can be restored by pulsatile administration of GnRH (Sakurai et
al., 1992).  These data indicate a progesterone inhibition of GnRH secretion, and a stimulatory
effect of GnRH at the level of the gonadotrope.  Furthermore, GnRH antagonists have been
found to decrease gonadotropin secretion and follicular growth indicating a direct or indirect role
of GnRH at the level of the pituitary and gonad (Lopez-Alonso et al., 2005).  These data further
substantiate the importance of GnRH in the regulation of gonadotropin secretion and gonad
function, as well as demonstrate the similarities in the caprine estrous cycle and that of other
farm species.   
The increasing knowledge of the physiological role of GnRH in caprine reproduction is
proving beneficial for managing reproduction.  For instance, GnRH therapy has shown promise
for inducing cyclicity during anestrus.  Various methods have been studied regarding induction
of ovulation in anestrous does.  Of these, the most effective involve progesterone pessaries in
conjunction with GnRH or gonadotropins (Bretzlaff and Romano, 2001; Whitley and Jackson,
2004).  Progesterone-priming in conjunction with hourly injections of GnRH induced an LH
surge and ovulation in seasonally anoestrous goats (Knight et al., 1988).  In many instances, the
estrus was infertile after a labor intensive treatment regimen.  In few cases, GnRH analogs have
proven successful at inducing ovulation.  Buserelin acetate, a relatively less potent analog of
GnRH, administered in conjunction with progesterone-priming, has induced LH secretion and
ovulation (Medan et al., 2002).  Similar to other domestic species, continuous infusion of GnRH
results in down-regulation of gonadotropin secretion in goats (Porter et al., 1997b).  This limits
the use of potent analogs or bolus injections in caprine synchronization schemes.  Chorionic
gonadotropins have shown promise at inducing ovulation in conjunction with progesterone
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treatment, but generally produce antibodies with continued use (Ritar et al., 1984; Bramley et al.,
2004).  A long-term physiologic GnRH therapy might be applicable in this area.  
Rationale for Present Experiments
Significant progress has been made in the discovery and development of alternative
hormone therapies.  Plasmid-mediated gene transfer is a novel delivery technique developed in
recent years to improve hormone therapy.  This technology is being applied to increase efficacy
or improve practicality of hormone delivery.  Unique plasmids can be constructed to
accommodate a specific protein at a specific expression level.  In the horse industry, GnRH and
GHRH have drawn interest for their effects on reproduction and performance.  Plasmid-mediated
gene transfer technologies could be applied to improve the utilization of these hormones in
equine production.  For these reasons, the experiments reported herein were designed 1) to test
known plasmids and their delivery technologies in the horse and 2) to develop and apply novel
plasmids in the horse and goat with the goal of increasing reproductive efficiencies of these two
species.  To this end, plasmids were constructed to express GHRH and GnRH in muscle tissue. 
A novel electroporation technique was evaluated for transfection efficacy in the horse and goat. 
Stallions were treated with plasmids expressing GHRH and GnRH to evaluate the effects on the
reproductive axis and seminal characteristics.  Subsequently, goat does were treated with the
GnRH expressing plasmid to evaluate the effects of GnRH on inducing ovulation during the
non-breeding season.  
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CHAPTER II
REGULATION OF THE EQUINE GROWTH HORMONE AXIS BY
ELECTROPORATIC DELIVERY OF A PLASMID ENCODING GHRH: 
EFFECTS ON SEMINAL CHARACTERISTICS
Introduction
Growth hormone treatment of the horse has been evaluated as an enhancer of the
cardiovascular system (McKeever et al., 1997), the musculoskeletal and the immune systems
(Malinowski et al., 1997; Smith et al., 1999), and the reproductive axis (Cochran et al., 1999;
Storer et al., 2005).  Only a few beneficial results have been attributed to GH treatment of
horses, which include increased granulocyte number and musculation in aged mares
(Malinowski et al., 1997), increased number of small follicles on the ovaries (Cochran et al.,
1999) and increased accessory sex gland function (Storer et al., 2005).  No one yet has examined
the effects of GH on pathologies including stallion subfertility, rhabdomyolysis, and laminitis,
due in part to the cost and availability of GH for chronic treatment.  Traditional hormone
therapies in domestic animals and humans involve routine intramuscular injections of short-lived
protein preparations.  These treatments are often painful, distressful, and inconvenient for both
the treated animals and humans administering the injections.  A relatively new technology, based
on mammalian plasmid delivery, has made it possible to provide months of therapy with a single
injection.  A plasmid can be injected into muscle tissue where it functions comparable to
chromosomal DNA.  Previous shortcomings of the technology were low expression levels
brought about by minimal cellular incorporation (Danko and Wolff, 1994; Tsurumi et al., 1996). 
Newer technologies have made it possible to incorporate DNA into mature mammalian cells for
production of encoded peptides in vivo.  The objective of the present experiment was to evaluate
a novel intramuscular plasmid-mediated hormone delivery system for the horse consisting of a
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plasmid encoding GHRH, which if effective, would provide information on the effects of a
long-term elevation of plasma GHRH concentrations on the GH axis and reproductive axis of the
stallion.  
Materials and Methods
Experiment 1.  Assessment of muscle groups for plasmid delivery.  Nine light-horse
geldings, 5 to 15 yr of age, weighing between 500 and 600 kg [body condition scores (BCS;
Henneke et al., 1983) of 6 to 8], were maintained on native grass pasture with supplemental grass
hay as needed to maintain body condition.  On d 0 (April 19, 2005), 3 geldings received
electroporatic delivery of the plasmid, pSEAP (Figure 2.1; a muscle-specific plasmid expressing
secreted embryonic alkaline phosphatase; provided by ADViSYS, Inc. Woodlands, TX) into one
of 3 unique muscle groups [splenius (neck), pectoralis (chest), and semitendinosus (rump)].  
The plasmid was delivered as 2 mg of DNA in 2 mL WFI (water for injection) + 0.1%
PLG (poly-L-glutamate) into the select muscle site.  In preparation for injection and
electroporation of the plasmid, horses were first sedated with 1.1 mg/kg of xylazine and 0.02
mg/kg of butorphanol administered i.v. to effect; the delivery site was then clipped and sanitized
with chlorahexadine.  Subsequently, the electrode needle array portion of the Electrokinetic
Device (EKD; provided by ADViSYS, Inc.  Woodlands, TX) was inserted.  The needle
electrodes consisted of a mounted circular array (1 cm diameter) of 5 evenly spaced, 21-gauge
solid stainless steel electrodes (2 cm in length) mounted on a nonconductive plastic disc.  After
insertion of the EKD, the plasmid was injected i.m. via a 21-gauge needle into the center of the
needle array.  Eighty seconds after plasmid injection, a constant current was delivered at 0.4 to
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Figure 2.1.  Map of secreted embryonic alkaline phosphatase plasmid (pSEAP). The 5019 bp
circular plasmid contains the c5-12 synthetic promoter and the gene for SEAP (provided by
ADViSYS, Inc. Woodlands, TX).  The plasmid is used extensively as a reporter for in vivo and
in vitro studies.
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Jugular blood samples were collected via venipuncture on d 0 (before injection), 3, 7, 10,
14, 17, 21, 24, 27, and 30 relative to treatment.  Blood samples were immediately centrifuged
(1,600 x g at 5°C for 15 min) and plasma was harvested and frozen at -15°C until assay. Plasma
from daily samples was analyzed for SEAP by chemiluminescent assay (Phospha-Light System,
Applied Biosystems, Bedford, Massachusetts).
Experiment 2.  Effects of electroporatic delivery of a plasmid encoding for GHRH. 
Twelve light-horse stallions, 2 to 24 yr of age, weighing between 500 and 600 kg (BCS of 4 to
6), were paired based on age and weight. Stallions were then randomly allotted so that each
treatment was represented within each pair. Each stallion received either i.m. electroporatic
delivery of pGHRH (Figure 2.2; a muscle-specific plasmid expressing porcine GHRH; provided
by ADViSYS, Inc., Woodlands, TX; n = 6) or pSEAP (n = 6).  The plasmids were delivered as 2
mg of DNA in 2 mL WFI + 0.1% PLG as described in Experiment 1.  
Blood samples were collected via jugular venipuncture into heparinized tubes on d 0, 1,
5, 8, 12, 15, 20, 22, and 29 relative to injection for assessment of GHRH and SEAP
concentrations (June 19, 2006).  
On d 22, all stallions received indwelling jugular catheters for frequent blood sampling to
characterize the GH secretory patterns of the 2 groups.  Catheters were inserted at -60 min, and
blood samples were collected into a heparinized tube at 0, 10, 20, 30, 45, 60, 90, 120, 150 min.  
Blood samples were immediately centrifuged (1,600 x g at 5°C for 15 min) and plasma
was harvested and stored frozen (-15°C) until assay.  Plasma samples were analyzed for SEAP
by chemiluminescent assay (Phospha-Light System).  Concentrations of GH and IGF-I were
determined by RIA previously validated for horse tissues as described by Thompson et al. (1992)














Figure 2.2.  Map of growth hormone releasing hormone plasmid (pGHRH).  The 2505 bp
circular plasmid contains the c5-12 synthetic promoter and the gene for GHRH (provided by
ADViSYS, Inc. Woodlands, TX; Draghia-Akli et al., 1999).
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Semen was collected from all stallions every other day for 14 d beginning 3 wk before
treatment and then again beginning on d 30 relative to treatment.  Semen evaluation was
conducted on the last 4 ejaculates from each stallion (Pickett et al., 1976).  Gel volume, gel-free
volume, progressive motility, concentration, and general sperm morphology were assessed for
each ejaculate.  Morphological characteristics evaluated were head, midpiece, and tail
abnormalities and proximal and distal droplets.  Gel-free semen was fixed in 2% buffered
formol-saline and 100 sperm from each ejaculate were analyzed with phase contrast microscopy
(Blanchard et al., 2003).
Data from blood collections were analyzed by ANOVA for effects of treatment and time
and the treatment by time interaction as a randomized block design with repeated measures using
SAS mixed procedure (SAS Institute Inc., Cary, NC).  Seminal characteristics were analyzed for
effects of treatment and period and the treatment by period interaction using SAS mixed
procedures. Differences at individual time points were determined by the least significant
difference (LSD) test (Steel et al., 1980) when a significant F (P < 0.05) was detected. Plasma
concentrations of SEAP in Experiment 2 were adjusted as percent change from individual
pretreatment means to account for individual variation in assay baselines.
Results
Visual appraisals of the electroporation sites were conducted in both experiments.  No
noticeable swelling was detected beyond 24 h after injection in any of the geldings or stallions.
Experiment 1.  Concentrations of SEAP increased (P < 0.01) in jugular plasma after
electroporation of the SEAP-expressing plasmid, pSEAP, at all 3 muscle sites.  The greatest (P <


















Figure 2.3.  Mean plasma concentrations of SEAP for samples collected 
twice weekly in response to electroporation with pSEAP (time 0) in the 
neck (splenius), chest (pectoralis), or rump (semitendinosus) muscle.  
Concentrations of SEAP increased over time (P < 0.05) and were greatest
(P < 0.05) when delivered in the chest.  The pooled SEM was 0.11 ng/mL. 
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Experiment 2.  Plasma GH concentrations measured by frequent blood sampling on d 22
indicated that stallions treated with the GHRH-expressing plasmid maintained a constant average
GH concentration throughout the blood sampling period, while GH concentrations in stallions
treated with the pSEAP plasmid declined (P < 0.05; Figure 2.4).  However, in plasma harvested
twice weekly, GH concentrations were not different between treatment groups (Figure 2.5). 
Concentrations of IGF-I were increased (P < 0.05) but remained within the physiological range
in stallions treated with pGHRH (Figure 2.5).  As expected, SEAP concentrations were elevated
(P < 0.05) in stallions treated with pSEAP (Figure 2.5) but not in stallions receiving the GHRH
plasmid.  
Semen evaluation demonstrated that stallions treated with pGHRH had a decrease (P <
0.05) in gel-free volume, an increase (P < 0.05) in percentage of normal spermatozoa, a decrease
(P < 0.05) in percentage of head abnormalities, and a tendency (P < 0.1) of increased volume of
gel (Figure 2.6).  Other semen characteristics (i.e., concentration of spermatozoa, midpiece
abnormalities, and tail abnormalities) did not differ between treatment groups.
Discussion
In Experiment 1, plasmid injection i.m. followed by electroporation proved to be an
effective delivery system for the pSEAP plasmid in the horse.  As indicated by assay of
peripheral SEAP concentrations, i.m. electroporation was muscle-specific in the horse, but
seemed to be differentially expressed, or differentially absorbed, in the 3 different muscle
groups.  The response to plasmid electroporation seemed to be fairly reliable and consistent
when conducted in the pectoralis muscle.  Decreased means for SEAP concentrations in geldings
treated in the splenius and semitendinosus indicated a greater variation among individual
subjects and a relatively minimal response amongst the group.  Efficacy of the treatment and
accessibility at the site of the pectoralis make it an ideal treatment site for application of
Figure 2.4.  Mean plasma concentrations of GH in frequent samples 
collected on d 22 in pGHRH- and pSEAP-treated stallions.  Differences 
between groups for plasma GH concentrations at individual time points are 
indicated (*P < 0.05; +P < 0.1).  Pooled SEM was 2.3 ng/mL.
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Figure 2.5.  Mean plasma concentrations of GH and IGF-I and % of pretreatment SEAP 
concentrations in samples collected twice weekly in response to electroporation with 
pGHRH or pSEAP on d 0.  Concentrations of GH did not differ between groups.  
Concentrations of IGF-I were increased (P < 0.05) in pGHRH-treated stallions, and 
concentrations of SEAP increased (P < 0.05) in pSEAP-treated stallions.  Differences 
between groups (P < 0.05) are indicated by asterisks.  Pooled SEM were 5.8, 33, and 27 
ng/mL for GH, IGF-I, and SEAP concentrations, respectively.
28
Figure 2.6.  Mean seminal characteristics for pGHRH-and pSEAP-treated stallions 
from ejaculates collected 3 wk prior to treatment (p1) and on d 30 relative to
treatment (p2).  Stallions treated with pGHRH had a decrease (P < 0.05) in gel-free 
volume, an increase (P < 0.05) in percentage of normal spermatozoa, a decrease 
(P < 0.05) in percentage of head abnormalities, and a tendency (P < 0.1) of increased 
volume of gel.  Error bars represent pooled SEM and asterisks indicate differences
from other groups and periods (* = P < 0.05 and ** = P < 0.1). 
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this technique in the horse industry.  Thus, the pectoralis was chosen as the site for
electroporation in Experiment 2.
It should be noted that SEAP, being foreign to the adult horse, is recognized as such and
is eventually cleared by the immune system (Gronevik et al., 2005).  This results in a sharp,
transient increase in plasma concentrations of SEAP (after electroporation) followed by a
similarly sharp reduction. In pigs, electroporation of a plasmid encoding the SEAP gene resulted
in peak plasma SEAP concentrations by d 10 before beginning to decline (Khan et al., 2003b;
Draghia-Akli and Fiorotto, 2004).
The pSEAP plasmid was chosen in Experiment 1 as a model with known efficacy in
other species (Draghia-Akli et al., 2002; Gronevik et al., 2005) that provided an easily
measurable protein product not normally found in adult stallions.  The pSEAP and pGHRH
plasmids contain a similar synthetic muscle-specific promoter and therefore would be expected
to be transcribed in a similar fashion.  Used as a control in the second experiment to confirm
electroporation success, pSEAP expressed SEAP in stallions under the same conditions as
pGHRH.  This would indicate that pGHRH should have expressed GHRH at a similar rate in the
stallions in Experiment 2.  Assuming that the expression of the 2 proteins was similar, plasma
concentrations of GHRH would be expected to be longer lived than those of SEAP due to its lack
of immunogenicity in the horse.
The pulsatility of plasma GH secretion may have been a factor in measuring changes
associated with GHRH stimulation directly.  Therefore, in Experiment 2, IGF-I concentrations
were considered indicative of pGHRH efficacy.  The response in IGF-I concentrations is
consistent with a prolonged expression of GHRH beyond 30 d.  Variation in IGF-I
concentrations in the pGHRH-treated stallions was considerably greater than that of the pSEAP
group, possibly indicating the need for further development of the delivery technique.  Variation
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in the increase in IGF-I was likely due to differential expression between individuals or
compromised cellular incorporation of the plasmid.
Plasma GH concentrations, evaluated twice weekly, were pulsatile and did not indicate
differences associated with pGHRH treatment.  This is consistent with studies in humans.  Vance
and colleagues (1985) reported that GHRH infusion did not affect basal plasma GH
concentrations.  Conversely, GH pulses were augmented and IGF-I concentrations were
increased.  In hindsight, the current experiment might have been improved by administration of a
GH secretagogue to evaluate any perturbation or augmentation of the GH response in pGHRH-
treated stallions.  As an alternative, frequent blood sampling was conducted to better characterize
the GH response to pGHRH. 
Frequent blood sampling on d 22 indicated a differential response over time in plasma
GH concentrations.  The initial difference in GH concentrations may have been misleading due
to the influence of several control stallions exhibiting pulses in GH just prior to the sampling
period.  It appeared that concentrations of GH were declining, perhaps after abrupt secretion
driven by excitement at catheterization (stallions were catheterized 1 hr prior to the first blood
sample).  Previous studies have shown that epinephrine administration, physical exercise, or
restraint with a twitch cause acute increases in plasma GH concentrations (Thompson et al.,
1992).  Therefore, samples collected later in the sampling period would better represent basal
GH secretion for the groups.  By 120 min, the variability in the samples had decreased, and basal
secretion was greater in the pGHRH-treated group.  
Previously, it was reported that stallions treated daily with recombinant equine GH had
increased accessory sex gland function (Storer et al., 2005).  Stallions in the present study only
exhibited a tendency toward increased volume of gel.  The decrease in number of head
abnormalities and gel-free volume reported herein are in contrast to that previously reported. 
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Head abnormalities, in the present study, were analyzed using phase contrast imaging which is
more sensitive to head abnormalities than the eosin-nigrosin stain used in the earlier study.  The
improved technique may have detected abnormalities that were overlooked in the previous study. 
Also, the mean number of pretreatment head abnormalities was greater in the pGHRH-treated
group.  This was partially due to one stallion that displayed an abnormally high number of sperm
head abnormalities.  In post treatment morphological assessments, the number of head
abnormalities displayed by this stallion was dramatically reduced.  In rats, GH treatment
improved recovery of spermatogenesis after pharmacologically induced testicular damage (Satoh
et al., 2002), and IGF-I treatment improved the morphology of epididymal spermatozoa (Vickars
et al., 1999).  This may indicate the ability of GH and/or IGF-I to improve viability and
longevity of spermatozoa in the epididymus.  There are no reports of decreased gel-free volume
in response to GH treatment.  Further studies are needed to clarify this issue.    
In conclusion, it has been shown that electroporatic-enhanced plasmid delivery, shown to
be effective in other species (Brown et al., 2004; Draghia-Akli and Fiorotto, 2004), can be used
to cause the production of the directed protein (SEAP) in the horse.  Of the muscle groups tested,
the pectoralis produced the greatest amount of protein measured in the blood.  In addition, this
novel plasmid-mediated treatment, used to deliver pGHRH DNA into the muscle, resulted in an
enhancement of plasma IGF-I concentrations for at least 30 d, and allowed for the evaluation of
long-term effects of elevated IGF-I levels on stallion reproduction.  Such treatments may be
beneficial in the equine industry for improving ejaculates of stallions collected for artificial
insemination or natural breeding.  Further investigation involving this plasmid needs to be
conducted, particularly in the subfertile stallion.  This technique should also be useful for
evaluation of other hypothalamic and pituitary hormones by incorporating other cDNA into the
plasmid for evaluation of the effects on other physiological systems and pathologies in the horse. 
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CHAPTER III
REGULATION OF THE STALLION REPRODUCTIVE AXIS BY 
ELECTROPORATIC DELIVERY OF A PLASMID ENCODING GNRH
Introduction
Enhancement of fertility in the normal and subfertile stallion could be economically
beneficial to horse breeders.  Many popular stallions are limited by their reproductive capacity
and cannot meet the demands of the industry.  Increasing the libido and sperm output of these
stallions could increase the number of breedings attained in a particular breeding season. 
Furthermore, stallion reproductive capacity is substantially reduced during the winter. 
Gonadotropin releasing hormone (GnRH) therapy has shown promise as a treatment for
improving gonadotropin and testosterone secretion in these scenarios.  Chronic, pulsatile
administration of GnRH increases LH and testosterone secretion but is less effective on semen
motility in stallions (Blue et al., 1991).  Pulsatile therapy is, however, impractical due to the
labor needed and the long-term nature of the treatment.  Long-lasting, potent analogs of GnRH
initially increase gonadotropin concentrations but subsequently down-regulate gonadotropin
production (Boyle et al., 1991; Johnson et al., 2003).  The aim of the current experiment was to
evaluate a novel plasmid-mediated delivery system for extrahypothalamic GnRH expression. 
The plasmid includes a muscle specific promoter followed by a construct comprised of bases
1-99 of the porcine GnRH gene (Weesner et al., 1997).  The plasmid was designed for long-term
expression of GnRH with the goal of improving the production of gonadotropins and
testosterone in the stallion.  
Materials and Methods
Plasmid preparation.  The plasmid designed for this experiment (pGnRH) was generated
from pGHRH, a muscle-specific plasmid expressing porcine GHRH provided by ADViSYS, Inc. 
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Woodlands, TX (Draghia-Akli et al., 1999).  The plasmid was reconstructed to replace the
existing GHRH cDNA sequence with the cDNA encoding GnRH by enzymatic cleavage at the 5'
Nco I and 3' Hind III sites.  A new cDNA insert was constructed for alternative expression of
GnRH based on the porcine gene for GnRH (Weesner et al., 1997; GeneBank accession
#L32864).  The constructed insert included bases 1 through 99 of the porcine GnRH gene
modified to include an Nco I restriction site at the 5' end and two 3' stop codons in conjunction
with a Hind III restriction site.  The complete cDNA insert was generated by PCR from two
overlapping primer templates [5'-CCATGGAGCCAATTCCGAAACTTCTAGCCGGACTT
CTGCTGCTGACTCTGTGTGTAGTGGGCTGC-3' (65 bp) and 5'-AAGCTTTCATTATCC-
AGGGCGCAATCCATAGGACCAGTGTTGGCTGGAGCAGCCCACTACACACAGAGT-3'
(69 bp)] and extended with primers designed for annealing at the generated 5' and 3' ends
[5'-CCATGGAGCCAATTCCGAAA-3' (20 bp) and 5'- AAGCTTTCATTATCCAGGGCG-3' 
(21 bp)].  The resulting PCR product was cloned using the TOPO XL PCR Cloning Kit (Gibco
Invitrogen).  Colonies were selected by kanamycin resistance and plasmid DNA was purified via
QIAfilter Plasmid Midi Kit (Qiagen Inc., Valencia, CA).  The sequence of the purified DNA was
then verified by PCR by personnel in the Division of Biotechnology and Molecular Medicine,
Louisiana State University School of Veterinary Medicine.  Both the TOPO-XL vector and the
pGHRH plasmid were simultaneously double-digested with restriction endonucleases Nco I and
Hind III (Gibco Invitrogen) for 24 h at 37º C.  The digested plasmid and insert products were
then separated by agarose gel electrophoresis and purified with the PureLink Gel Extraction Kit
(Gibco Invitrogen).  The products were then ligated using the DNA Ligation Kit Ver.1 (Takara
Mirus Bio Inc., Madison, WI).  The resulting plasmid was transfected into a DH alpha E.coli cell
line and selected based on kanamycin resistance.  Plasmid DNA was purified from resulting
colonies with QIAfilter Plasmid Midi Kit (Qiagen) and the sequence verified by PCR.  Select
35
colonies were grown up and plasmid DNA was purified with EndoFree Plasmid Giga Kit
(Qiagen).
Transfection of mouse myoblast cells.  Mouse myoblast cells (Sol8), obtained from the
American Type Culture Collection (Manassas, VA; CRL-2174), were transfected with the
plasmid to evaluate the efficacy of the plasmid in muscle tissue.  Prior to transfection, cells were
grown to 70 to 80% confluency in Dulbecco's modified Eagle's medium (DMEM; Sigma, St. 
Louis, MO) supplemented with 20% fetal bovine serum (Gibco Invitrogen) and 1%
penicillin-streptomycin (Gibco Invitrogen) at 37°C in a humidified environment of 5% CO2 and
95% air.  At 80% confluence, media was replaced with Dulbecco's modified Eagle's medium
supplemented with 2% heat-inactivated horse serum (Gibco Invitrogen) and 1%
penicillin-streptomycin (Gibco Invitrogen).  Cells were then transfected with 4 µg of pGnRH (n
= 4), or no DNA (n = 1) via Fugene 6 Transfection Reagent (Roche Applied Sciences,
Indianapolis, IN).  Transfected cells were incubated for 72 h at 37°C in a humidified
environment of 5% CO2 and 95% air.  Media was collected at 72 h, and GnRH expression was
verified by RIA of culture media for GnRH.   
Treatment of stallions.  Ten reproductively sound stallions ranging in age from 2 to 25 yr
were used.  They were allotted to 3 groups such that average age and weight were similar for the
groups.  On d 0, stallions in the first group received i.m. electroporation of 2 mg pGnRH in 2 mL
of vehicle (WFI + 0.1% PLG; n = 3); the second group received 4 mg of pGnRH in 2 mL vehicle
(n = 3); and the third group received 2 mg of pSEAP in 2 mL of vehicle (n = 4) as described for
Experiment 1.  Preparation and anesthesia of the stallions and injection and electroporation of
the plasmids were performed as described in Chapter II.
Blood samples were collected from all stallions twice weekly beginning 1 wk before
treatment through 6 wk after treatment.  On d 21, stallions were fitted with an indwelling jugular
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catheter. One hour later, all stallions received a challenge injection of GnRH (0.1 µg/kg of BW,
i.v.; Sigma), and blood samples were collected at -20, -10, 0, 10, 20, 30, 60, 90, 120, 150, 180,
210, and 240 min relative to injection to assess the pituitary-gonadal response to GnRH.  These
blood samples were analyzed for concentrations of LH, FSH, and testosterone.  
Semen collection was conducted daily for 6 d starting 30 d after plasmid injection. 
Semen evaluation (Pickett et al., 1976) was conducted on the last 3 ejaculates from each stallion. 
Gel volume, gel-free volume, progressive motility, concentration, and general sperm
morphology were evaluated.  Morphological characteristics (head, midpiece, and tail
abnormalities and proximal and distal droplets) were assessed in gel-free semen fixed in 2%
buffered formol-saline; 100 sperm from each ejaculate were analyzed by viewing under phase
contrast microscopy (Blanchard et al., 2003).
Blood collected during frequent and daily sampling was immediately centrifuged (1,600
x g at 5°C for 15 min) and plasma was harvested and stored at -15°C until assay.  All samples
were analyzed as previously described for SEAP (Phospha-Light System), LH (Thompson et al.,
1983a), FSH (Thompson et al., 1983b), and testosterone (Diagnostic Systems Laboratories,
Webster, TX).  
Tissue culture data were analyzed using t-test to compare the mean of the 3 transfected
cell cultures to zero; there was only one nontransfected culture, and there was no detectable
GnRH in that medium.  
Data obtained from blood collections in the stallion experiment  were analyzed for effects
of treatment and time and the treatment by time interaction as a randomized block design with
repeated measures using SAS mixed procedure (SAS Institute  Inc., Cary, NC).  Seminal
characteristics were analyzed for effects of treatment and time and the treatment by time
interaction via the mixed procedures of SAS.  Differences at individual time points were
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determined by LSD test when a significant F (P < 0.05) was detected. Plasma concentrations of
LH, FSH, testosterone and SEAP were adjusted to net differences from pretreatment means prior
to analysis to account for individual variation in resting hormone concentrations.
Results
Tissue culture of Sol8 mouse myoblast cells transfected with pGnRH or no DNA
indicated increased (P < 0.01) expression in cells transfected with pGnRH (Figure 3.1).  In the
stallions, responses for the 2 mg and 4 mg DNA injection were similar in treated stallions; thus,
the groups were combined and referred to collectively as "pGnRH-treated.”  Treatment with
pGnRH increased (P < 0.05) plasma concentrations of testosterone above controls in blood
samples collected twice weekly by d 35 post treatment (Figure 3.2).  The increase in testosterone
concentrations from treated stallions was maintained for the duration of sample collection (d 58). 
Plasma concentrations of LH and FSH in samples collected twice weekly were not different (P >
0.1) between treatment groups (Figure 3.2).  Frequent blood sampling conducted around the
GnRH challenge revealed an increased (P < 0.01) response in plasma LH concentrations and a
tendency (P =0.098) for increased response in testosterone concentrations (Figure 3.3). 
Conversely, concentrations of FSH were similar (P > 0.1) between groups in response to the
GnRH challenge (Figure 3.3).  Control stallions responded to pSEAP with increased (P < 0.01)
plasma concentrations of SEAP (Figure 3.4).  Seminal characteristics did not differ (P > 0.1)
between groups (Figure 3.5).  
Discussion
Treatment with pGnRH increased testosterone production gradually through the end of
the sampling period (58 d).  Similarly, Blue and colleagues (1991) reported an increase in
testosterone secretion in stallions in response to long-term, pulsatile (10 µg every 2 h)
Figure 3.1.  Tissue culture concentrations of GnRH in media harvested 
from Sol8 mouse myoblasts cells transfected with pGnRH or no DNA 
(control).  Cells transfected with pGnRH had increased (P < 0.01) expression 
of GnRH.  The asterisk indicates GnRH concentration was below detectable 





















Figure 3.2.  Mean plasma concentrations expressed as net differences 
from pretreatment means for testosterone, LH, and FSH in samples collected 
twice weekly after pGnRH and pSEAP treatment on d 0.  Testosterone 
concentrations increased (P < 0.05) in pGnRH-treated stallions.  Concentra-
tions of LH and FSH were similar between groups.  Asterisks indicate 
differences between groups (P < 0.05).  Pooled SEM were 0.33, 0.46, and 
0.81 for testosterone, LH, and FSH, respectively.
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Figure 3.3.  Plasma concentrations expressed as net differences from  
pretreatment means for testosterone in pGnRH- and pSEAP-treated stallions 
after GnRH administration (time 0) on d 21.  Stallions treated with pGnRH
had a greater (P < 0.05) LH response to GnRH; concentrations of FSH were 
similar between groups.  Treatment with pGnRH tended to increase (P < 0.1) 
the testosterone response to GnRH administration.  Asterisks indicate 
differences between means (P < 0.05).  Pooled SEM were 0.22, 3.8, and 0.24 
ng/mL for LH, FSH, and testosterone, respectively.
40
Figure 3.4.  Plasma concentrations of SEAP in pGnRH- and pSEAP-treated 
stallions expressed as net difference from pretreatment means.  Treatment 
with pSEAP increased (P < 0.05) plasma concentrations of SEAP.  Asterisks 
indicate differences between groups (P < 0.05).  Pooled SEM was 0.15 ng/mL.
41
Figure 3.5.  Seminal characteristics from stallions treated with pGnRH or 
pSEAP and evaluated on d 30 relative to treatment.  Seminal characteristics
evaluated were similar (P > 0.1) between groups.  Error bars indicate 
pooled SEM for each characteristic. 
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administration of GnRH.  Blue et al. (1991) also reported that continuous infusion of GnRH at a
similar rate was not effective at increasing testosterone or LH secretion.  The exact nature of
GnRH expression from pGnRH in this experiment is unknown.  Because plasma concentrations
of GnRH were not directly measured, it is assumed that expression is similar to that determined
for SEAP.  However, compared to GnRH, SEAP has a relatively long half-life in peripheral
blood, therefore its concentrations may not necessarily be indicative of the secretion of the short
half-life peptide.  Based on this information, pGnRH expression may be more physiological than
constant infusion of GnRH, thereby enabling an effect on testosterone secretion as is seen with
pulsatile administration.  
Treatment with pGnRH was not effective at increasing basal concentrations of
gonadotropins but did increase the LH response to a physiologic dose of GnRH on d 21.  It is
likely that increasing concentrations of testosterone provided negative feed back adequate to
inhibit LH secretion from the pituitary (Thompson et al., 1979) while production was still being
stimulated by GnRH.  In anestrous mares, daily injections of a GnRH analogue potentiated the
LH response to each consecutive injection, while basal LH concentrations between GnRH
injections were similar to controls (Gentry et al., 2002).  This indicates an ability of GnRH to
increase intracellular production of LH without noticeable increases in basal secretion.  In the
present experiment, intracellular production of LH may have been augmented at the same time
that steroid inhibition was minimizing LH secretion.  Intuitively, increased levels of testosterone
should have been accompanied by a reduction in LH secretion.  Maintenance of basal LH
concentrations in the treated group, therefore, likely indicated a positive effect of pGnRH.
Horses have been reported to be fairly resistant to down-regulation by GnRH and its
analogs.  Boyle and colleagues (1991) used osmotic pumps to deliver buserelin (a potent GnRH
analogue) to assess the long-term effects of high levels of GnRH.  In their study, LH and
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testosterone concentrations were initially increased and subsequently decreased below baseline. 
These data are in contrast to the results herein, indicating GnRH expression from pGnRH did not
attain levels required for down-regulation.  Current interest in the horse industry has included
utilization of potent analogs for regulating reproductive related behavior.  Future efforts might be
directed towards evaluating the effects of improved expression or incorporating genetic
expression of GnRH analogs into the plasmid for treatment of reproductive related behavior in
the horse.
Seminal characteristics were not altered when semen was evaluated on d 34 through 36,
in spite of the increased testosterone secretion.  Blue and colleagues (1991) similarly reported
that constant infusion or pulsatile administration of GnRH for 5 mo did not alter total number of
spermatozoa or progressive motility.  This may reflect the lack of perturbation in basal LH and
FSH secretion in response to pGnRH treatment.  Also, considerable differences in testosterone
secretion were not evident until d 35.  Differences attributed to the variation in testosterone
secretion may have been more evident if semen collection had been conducted later in the study.
Increased concentrations of SEAP in pSEAP-treated stallions confirmed the functionality
of the technology in the stallion.  As stated previously, SEAP concentrations may not adequately
reflect the expression pattern of GnRH.  The utilization of pSEAP as a control demonstrated that
the electroporation technique and the plasmid backbone operated appropriately.  Considering
that the pGnRH contains a similar backbone and was delivered with the same technique, it is
assumed that GnRH was expressed similar to SEAP, except that GnRH should not elicit an
immune response due to its small size and natural occurrence in the horse.
In conclusion, intramuscular plasmid delivery followed by electroporation seems to have
potential as an effective hormone delivery system for the horse.  The current experiment
indicated that the basic components of the GHRH and SEAP plasmids can be used to construct
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plasmids containing the DNA of other potentially beneficial peptides.  Such a plasmid was used
to facilitate evaluation of the effects of GnRH on the reproductive axis of the stallion.  Increased
testosterone production in the stallion was accompanied by a perturbation in LH secretion after
GnRH challenge.  Furthermore, the increase in testosterone production was not associated with
adverse physiological effects with regard to down-regulation of gonadotropins or semen
morphology.  These results warrant future research into the possible beneficial uses of this
technology for the equine industry.  
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CHAPTER IV
REGULATION OF THE REPRODUCTIVE AXIS OF GOAT DOES BY
ELECTROPORATIC DELIVERY OF A PLASMID ENCODING GNRH
Introduction
Reproductive seasonality is a natural phenomenon of many domesticated and exotic
species.  The seasonal variation in reproductive capacity for each species is relative to their
gestation length, allowing for birth of offspring during the most fertile environmental period. 
Environmental factors, including photoperiod, temperature, and nutrition, are influential factors
regulating seasonal reproductive recrudescence (Sharp, 1988; Gentry et al., 2002).  These
environmental stimuli indirectly regulate reproduction by modulating hypothalamic GnRH
secretion.  Treatment with GnRH and its analogs have shown promise at inducing reproductive
recrudescence during deep anestrus (Johnson, 1987; Turner and Irvine, 1991; Medan et al.,
2002).  Problems have arisen with these treatments due to an inability to mimic physiologic
GnRH secretion.  Native GnRH is short-lived in circulation and requires frequent administration
or continuous infusion to mimic physiologic secretion.  Potent analogs tend to down-regulate
gonadotropin production, especially in ruminants.  A more physiologic and long-term GnRH
therapy is needed to further investigate the potential use of GnRH in goat production systems. 
The goal of the current experiment was to develop a plasmid-based peptide delivery system for
the goat and to utilize the delivery system to produce a long-term GnRH therapy for the
anestrous doe in an attempt to reverse the seasonal anestrous state.    
Materials and Methods
Twenty anestrous doe goats ranging in age from 2 to 6 yr were selected on June 19, 2006. 
Does were maintained on a pelleted ration and supplemental grass hay as needed to maintain
body condition. A doe was determined to be seasonally anestrus based on plasma progesterone
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concentrations less than 0.5 ng/mL for 10 d with no signs of estrous behavior.  Does were paired
based on age and weight and were randomly allotted from each pair into 2 treatment groups. 
The groups received i.m. electroporatic delivery of the plasmid pGnRH or pSEAP (1 mg DNA in
1 mL WFI + 0.1% PLG; n = 10 per group), respectively.  The plasmids were injected into the
semimembranosus muscle as described in Chapter II.  
On d 21, 5 does from each treatment group were each implanted with one-half of a
Crestar implant (3 mg norgestomet; Intervet International Boxmeer, The Netherlands), which
was left in place for 10 d.  Blood samples were collected from all does via jugular venipuncture
into heparinized tubes every 3 to 4 d for 28 d with 2 pretreatment blood samples collected on d
-3 and d 0 relative to treatment.  Additional blood samples were collected on d 29 to 58 from
implanted does to characterize the response in plasma gonadotropins to implantation.  Does were
exposed to a sexually vigorous buck twice daily beginning 2 wk before treatment for the
detection of estrus.  
All blood samples were immediately centrifuged (1,600 x g at 5°C for 15 min) after
collection, and plasma was harvested and stored at -15°C.  All samples were analyzed as
previously described for SEAP (Phospha-Light System), LH (Thompson et al., 1983a), FSH
(Thompson et al., 1983b), and progesterone (Diagnostic Systems Laboratories, Webster, TX).  
Data from blood samples were analyzed for effects of treatment and time and the
treatment by time interaction as a randomized block design with repeated measures using SAS
mixed procedure (SAS Institute Inc., Cary, NC).  Data were analyzed through d 28 on all does,
and an additional analysis was conducted separately for d 21 to 58 on implanted does. 
Differences at individual time points were determined by LSD test when a significant F (P <
0.05) was detected.  To account for individual variation in resting hormone concentrations prior
to treatment, plasma concentrations of LH, FSH, and SEAP were calculated as the net
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differences from pretreatment means prior to analysis.  Pretreatment means of each individual
were subtracted from their subsequent data, and the analyses were performed on the differences. 
Results
Treatment with pGnRH did not influence (P > 0.1) plasma concentrations of LH and FSH
collected over the first 28 d (Figure 4.1).  As expected, does treated with pSEAP had increased
(P < 0.01) plasma concentrations of SEAP that returned to baseline by d 28 after treatment
(Figure 4.1).  Plasma concentrations of LH and FSH in blood samples collected from implanted
does gradually increased over time (P < 0.05) but were similar (P > 0.1) for the 2 treatment
groups (Figure 4.2).  Implantation on d 21 did not disrupt (P > 0.1) basal concentrations of
gonadotropins or induce estrus in either treatment group.  Lack of ovulation was indicated by
low levels of progesterone throughout the blood sampling period for both groups.  Estrus
detection, performed by twice daily exposure to the buck, revealed minimal signs of sporadic
estrus approximately 20 d after exposure to the buck in both treatment groups; these were not
associated with mounting or changes in measured hormonal parameters.  
Discussion
The primary goal of this experiment was to develop a mammalian plasmid-based gene
transfer system for the goat.  Treatment with pSEAP increased plasma concentrations of SEAP
in the control group as expected.  This confirmed that the pSEAP plasmid was effectively
delivered into the muscle of the goats, and SEAP was expressed and secreted.  Concentrations of
SEAP peaked around d 15 after treatment, similar to SEAP expression produced in previous
experiments conducted in horses.  Duration of SEAP expression, as indicated by plasma
concentrations, is believed to be limited by the immunogenicity of SEAP in adult mammals,
whereas, expression of immunoneutral protein products would be expected to persist beyond the
Figure 4.1.  Mean plasma concentrations expressed as net differences from
pretreatment means for LH, FSH, and SEAP in blood samples collected 
twice weekly from does relative to treatment with pGnRH or pSEAP on d 0.  
Concentrations of LH and FSH were similar between treatment groups.  
Concentrations of SEAP were increased (P < 0.05) in response to pSEAP
treatment.  Asterisks indicate differences between means (P < 0.05).  Pooled 
SEM were 0.05, 0.33, and 0.13 ng/mL for LH, FSH, and SEAP, respectively.
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Figure 4.2.  Mean plasma concentrations expressed as net differences 
from pretreatment means for LH and FSH in does treated with pGnRH or 
pSEAP on d 0 and implanted with progesterone (d 21 to 31).  Concentrations 
of LH and FSH increased over time (P < 0.05) in both treatment groups.  No 
differences were attributed to pGnRH treatment.  Pooled SEM were 0.11 and 
0.84 ng/mL for LH and FSH, respectively.
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30 d in the pSEAP control.  If the pGnRH plasmid were delivered and expressed as effectively as
the pSEAP plasmid, expression of pGnRH should have been adequate to elicit a desirable
outcome (increased gonadotropin secretion and ovarian activity).
A secondary goal of this experiment was to establish a GnRH secreting plasmid and
determine the effects of long-term GnRH therapy on the anestrous doe.  Given the results herein,
the efficacy of the plasmid for expression in the doe cannot be determined.  In stallions (Chapter
III), treatment with pGnRH resulted in a gradual increase in testosterone throughout the blood
sampling period (56 d) indicating a positive effect of the plasmid in the horse.  It is likely  that
does treated with pGnRH responded with expression of GnRH but the levels produced were not
sufficient to increase gonadotropins in the anestrous state.  Further research is needed to
determine whether does exhibiting nadir levels of gonadotropins during anestrus are capable of
responding to the pGnRH treatment.  
Current schemes for inducing ovulation in anestrous does include progesterone pessaries
in conjunction with GnRH or gonadotropins (Bretzlaff and Romano, 2001; Whitley and Jackson,
2004).  Progesterone-priming in conjunction with hourly injections of  GnRH was capable of
inducing an LH surge and ovulation in seasonally anoestrous goats (Knight et al., 1988). 
Therefore, the progesterone implant administered on d 21 after plasmid delivery, if accompanied
by sufficient GnRH secretion, should have been able to initiate ovulation.  Conversely,
continuous infusion of GnRH has been shown to result in down-regulation of gonadotropin
secretion (Porter et al., 1997b).  Although it is possible that expression of GnRH from pGnRH
overwhelmed the pituitary resulting in a down-regulation of receptors on the gonadotropes, it is
probably more likely that insufficient GnRH was secreted to cause an effect.
In conclusion, electroporation of plasmid DNA encoding SEAP did function in the goat
in a manner and to a degree similar to that observed other species, indicating that this technology
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may have potential for applications in goat management schemes and veterinary therapy.  The
role of GnRH in the anestrous doe could not be determined.  The anestrous doe may not be
responsive to chronic, low-level GnRH treatment.  Future efforts are needed to further evaluate
the applications of this novel technology in domestic livestock.
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 SUMMARY AND CONCLUSIONS
A novel, plasmid-based peptide delivery technique was studied in the horse and the goat. 
The technique was effective in producing peptide products in vivo in both species.  Treatment
with pSEAP resulted in increased plasma concentrations of SEAP in all instances.  Efforts at
exploiting the technique for increasing GHRH and GnRH in the stallion were successful within
limits, as determined by elevated plasma concentrations of IGF-I and testosterone, respectively. 
Treatment with pGHRH may have improved the seminal quality by increasing the number of
normal spermatozoa and decreasing the number of sperm head abnormalities.  This treatment
may have potential in the horse industry as a treatment for infertility in popular or geriatric
breeding stallions.  Elevated levels of testosterone resulting from treatment with pGnRH could
facilitate improved performance and libido in racing and breeding stallions.  
Trials aimed at increasing GnRH in the anestrous doe were inconclusive.  It could not be
determined whether pGnRH was not expressed in the does, or whether the expression and
secretion were too low to have effects on LH and FSH secretion.  It is also possible that a
chronic, low-level GnRH secretion down-regulated gonadotropins in the doe rather than
stimulating them.  A more pulsatile secretion pattern might be necessary to elicit LH secretion
accompanied by ovulation.
Although these first attempts to apply this novel plasmid delivery system to horses and
goats produced limited positive effects, this area of research has potentially limitless applications
for domestic livestock production and human medicine.  Subsequent research needs to focus on
the fine tuning of the technology to maximize the expression and secretion of produced peptides. 
54
REFERENCES
Acsadi, G., G. Dickson, D. R. Love, A. Jani, F. S. Walsh, A. Gurusinghe, J. A. Wolff, and K. E.
Davies. 1991. Human dystrophin expression in mdx mice after intramuscular injection of DNA
constructs. Nature 352:815-818.
Alberts, B., A. Johnson, J. Lewis, M. Raff, K. Roberts, and P. Walter. 2002. Manipulating
proteins, DNA, and RNA. Page 500 in Molecular Biology of the Cell. Fourth ed. Garland
Science, Taylor and Francis Group. New York, NY.
Alexander, S. L. and C. H. Irvine. 1987. Secretion rates and short-term patterns of
gonadotrophin-releasing hormone, FSH and LH throughout the periovulatory period in the mare.
J. Endocrinol. 114:351-362.
Allen, W. R., M. W. Sanderson, R. E. Greenwood, D. R. Ellis, J. S. Crowhurst, D. J. Simpson, 
and P. D. Rossdale. 1987. Induction of ovulation in anoestrous mares with a slow-release
implant of a GnRH analogue (ICI 118 630). J. Reprod. Fertil. Suppl. 35:469-478. 
Aurich, C., T. Gerlach, J. E. Aurich, and N. Parvizi. 1999. Seasonal variation and opioidergic
regulation of growth hormone release in cyclic, ovariectomized, and pregnant pony mares. Biol.
Reprod. 61:1575-1580.
Aurich, J. E., S. Kranski, N. Parvizi, and C. Aurich. 2003. Somatostatin treatment affects
testicular function in stallions. Theriogenology. 60:163-174.
Baker, A. H., A. Kritz, L. M. Work, and S. A. Nicklin. 2005. Cell-selective viral gene delivery
vectors for the vasculature. Exp. Physiol. 90:27-31.
Becker, S. E. and A. L. Johnson. 1992. Effects of gonadotropin-releasing hormone infused in a
pulsatile or continuous fashion on serum gonadotropin concentrations and ovulation in the mare.
J. Anim. Sci. 70:1208-1215.
Blanchard, L., D. D. Varner, J. Schumaker, C. C. Love, S. P. Brinsko, and J. P. Rodgers. 2003.
Examination of the Stallion for Breeding Soundness. Page 143 in Manual of Equine
Reproduction. 2nd ed. Mosby. St. Louis, MO.
Blue, B. J., B. W. Pickett, E. L. Squires, A. O. McKinnon, T. M. Nett, R. P. Amann, and  K. A.
Shiner. 1991. Effect of pulsatile or continuous administration of GnRH on reproductive function
of stallions. J. Reprod. Fertil. Suppl. 44:145-154.
Boyle, M. S., J. Skidmore, J. Zhang, and J. E. Cox. 1991. The effects of continuous treatment of
stallions with high levels of a potent GnRH analogue. J. Reprod. Fertil. Suppl. 44:169-182.
Bramley, T. A., D. Stirling, G. S. Menzies, and D. T. Baird. 2004. Reduced LH sensitivity in
vivo and in vitro of corpora lutea induced during anoestrus by GnRH, and during the late
breeding season, in Scottish Blackface ewes. J. Endocrinol. 183:517-526.
55
Bretzlaff, K. N. and J. E. Romano. 2001. Advanced reproductive techniques in goats. Vet. Clin.
North Am. Food Anim. Pract. 17:421-434.
Brown, P. A., W. C. Davis, and R. Draghia-Akli. 2004. Immune-enhancing effects of growth
hormone-releasing hormone delivered by plasmid injection and electroporation. Mol. Ther.
10:644-651.
Bureau, M. F., J. Gehl, V. Deleuze, L. M. Mir, and D. Scherman. 2000. Importance of
association between permeabilization and electrophoretic forces for intramuscular DNA
electrotransfer. Biochim. Biophys. Acta. 1474:353-359.
Capshaw, E. L., D. L. Thompson, Jr., K. M. Kulinski, C. A. Johnson, and D. D. French. 2001.
Daily treatment of horses with equine somatotropin from 4 to 16 months of age. J. Anim. Sci.
79:3137-3147.
Chatelain, P., D. Naville, O. Avallet, A. Penhoat, C. Jaillard, P. Sanchez, and J. Saez. 1991.
Paracrine and autocrine regulation of insulin-like growth factor I. Acta Paediatr. Scand. Suppl.
372:92-95.
Christensen, R. A., K. Malinowski, C. G. Scanes, and H. D. Hafs. 1997. Pulsatile release of
somatotropin related to meal feeding and somatotropin response to secretagogues in horses. J.
Anim. Sci. 75:2770-2777.
Cochran, R. A., A. A. Leonardi-Cattolica, M. R. Sullivan, L. A. Kincaid, B. S. Leise, D. L.
Thompson Jr., and R. A. Godke. 1999. The effects of equine somatotropin (eST) on follicular
development and circulating plasma hormone profiles in cyclic mares treated during different
stages of the estrous cycle. Domest. Anim. Endocrinol. 16:57-67.
Cohick, W. S., J. D. Armstrong, M. D. Whitacre, M. C. Lucy, R. W. Harvey, and R. M.
Campbell. 1996. Ovarian expression of insulin-like growth factor-I (IGF-I), IGF binding
proteins, and growth hormone (GH) receptor in heifers actively immunized against GH-releasing
factors. Endocrinology. 137:1670-1677.
Danko, I. and J. A. Wolff. 1994. Direct gene transfer into muscle. Vaccine. 12:1499-1502.
de Castro, T., E. Rubianes, A. Menchaca, and A. Rivero. 1999. Ovarian dynamics, serum
estradiol and progesterone concentrations during the interovulatory interval in goats.
Theriogenology. 52:399-411.
Draghia-Akli, R., K. K. Cummings, A. S. Khan, P. A. Brown, and R. H. Carpenter. 2003a.
Effects of plasmid-mediated growth hormone releasing hormone supplementation in young,
healthy Beagle dogs. J. Anim. Sci. 81:2301-2310.
Draghia-Akli, R., K. M. Ellis, L. A. Hill, P. B. Malone, and M. L. Fiorotto. 2003b.
High-efficiency growth hormone-releasing hormone plasmid vector administration into skeletal
muscle mediated by electroporation in pigs. FASEB J. 17:526-528.
56
Draghia-Akli, R., M. L. Fiorotto, L. A. Hill, P. B. Malone, D. R. Deaver, and R. J. Schwartz.
1999. Myogenic expression of an injectable protease-resistant growth hormone releasing
hormone augments long-term growth in pigs. Nature Biotechology. 17(12):1179-1183.
Draghia-Akli, R. and M. L. Fiorotto. 2004. A new plasmid-mediated approach to supplement
somatotropin production in pigs. J. Anim. Sci. 82 E-Suppl:E264-E269.
Draghia-Akli, R., A. S. Khan, K. K. Cummings, D. Parghi, R. H. Carpenter, and P. A. Brown.
2002. Electrical enhancement of formulated plasmid delivery in animals. Technol. Cancer Res.
Treat. 1:365-372.
Draghia-Alki, R. and L. A. Smith. 2003. Electrokinetic Enhancement of Plasmid Delivery In
Vivo. Page 245 in Gene Therapy: Therapeutic Mechanisms and Strategies. Marcel Dekker, Inc.
New York.
Evans, M. J. and C. H. Irvine. 1977. Induction of follicular development, maturation and
ovulation by gonadotropin releasing hormone administration to acyclic mares. Biol. Reprod.
16:452-462.
Evans, M. J., N. E. Kitson, S. L. Alexander, C. H. Irvine, J. E. Turner, N. R. Perkins, and J. H.
Livesey. 2002. Effectiveness of an antagonist to gonadotrophin releasing hormone on the FSH
and LH response to GnRH in perifused equine pituitary cells, and in seasonally acyclic mares.
Anim. Reprod. Sci. 73:37-51.
Farmer, C., P. Dubreuil, G. Pelletier, D. Petitclerc, P. Gaudreau, and P. Brazeau. 1991. Effects of
active immunization against somatostatin (SRIF) and/or injections of growth hormone-releasing
factor (GRF) during gestation on hormonal and metabolic profiles in sows. Domest. Anim.
Endocrinol. 8:415-422.
Fewell, J. G., F. MacLaughlin, V. Mehta, M. Gondo, F. Nicol, E. Wilson, and L. C. Smith. 2001.
Gene therapy for the treatment of hemophilia B using PINC-formulated plasmid delivered to
muscle with electroporation. Mol. Ther. 3:574-583.
Fitzgerald, B. P., S. L. Meyer, K. J. Affleck, and P. J. Silvia. 1993. Effect of constant
administration of a gonadotropin-releasing hormone agonist on reproductive activity in mares:
induction of ovulation during seasonal anestrus. Am. J. Vet. Res. 54:1735-1745.
Fortier, L. A., M. A. Kornatowski, H. O. Mohammed, M. T. Jordan, L. C. O'Cain, and W. B.
Stevens. 2005. Age-related changes in serum insulin-like growth factor-I, insulin-like growth
factor-I binding protein-3 and articular cartilage structure in Thoroughbred horses. Equine Vet. J.
37:37-42.
Frederickson, R. M., B. J. Carter, and A. M. Pilaro. 2003. Nonclinical toxicology in support of
licensure of gene therapies. Arlington, VA, USA, March 13-14, 2003. Mol. Ther. 8:8-10.
57
Garza, F., Jr., D. L. Thompson, Jr., D. D. French, J. J. Wiest, R. L. St George, K. B. Ashley, L.
S. Jones, P. S. Mitchell, and D. R. McNeill. 1986. Active immunization of intact mares against
gonadotropin-releasing hormone: Differential effects on secretion of luteinizing hormone and
follicle-stimulating hormone. Biol. Reprod. 35:347-352.
Gentry, L. R., D. L. Thompson, Jr., and A. M. Stelzer. 2002. Responses of seasonally
anovulatory mares to daily administration of thyrotropin-releasing hormone and(or)
gonadotropin-releasing hormone analogue. J. Anim. Sci. 80:208-213.
Gerard, M. P., D. R. Hodgson, R. R. Lambeth, S. P. Ray, and R. J. Rose. 2002. Effects of
somatotropin and training on indices of exercise capacity in Standardbreds. Equine Vet. J. Suppl.
34:496-501.
Gilbert, R. A., M. J. Jaroszeski, and R. Heller. 1997. Novel electrode designs for
electrochemotherapy. Biochim. Biophys. Acta. 1334:9-14.
Ginther, O. J. and K. Kot. 1994. Follicular dynamics during the ovulatory season in goats.
Theriogenology. 42:987-1001.
Gronevik, E., F. V. von Steyern, J. M. Kalhovde, T. E. Tjelle, and I. Mathiesen. 2005. Gene
expression and immune response kinetics using electroporation-mediated DNA delivery to
muscle. J. Gene Med. 7(2):218-27.
Guirnalda, P. D., K. Malinowski, V. Roegner, and D. W. Horohov. 2001. Effects of age and
recombinant equine somatotropin (eST) administration on immune function in female horses. J.
Anim. Sci. 79:2651-2658.
Hadley, M. E. 2000. Growth Hormones. Page 277 in Endocrinology Prentice-Hall, Inc. Upper
Saddle River, New Jersey.
Harrison, L. A., E. L. Squires, T. M. Nett, and A. O. McKinnon. 1990. Use of
gonadotropin-releasing hormone for hastening ovulation in transitional mares. J. Anim. Sci.
68:690-699.
Hart, P. J., E. L. Squires, K. J. Imel, and T. M. Nett. 1984. Seasonal variation in hypothalamic
content of gonadotropin-releasing hormone (GnRH), pituitary receptors for GnRH, and pituitary
content of luteinizing hormone and follicle-stimulating hormone in the mare. Biol. Reprod.
30:1055-1062.
Henneke, D.R., G.D. Potter, J. L. Kreider, and B. F. Yeates. 1983. Relationship between
condition score, physical measurements and body fat percentage in mares. Equine Vet. J.
15:371-372.
Hess, M. F., and J. F. Roser. 2005. A comparison of the effects of equine luteinizing hormone
(eLH), equine growth hormone (eGH) and human recombinant insulin-like growth factor
(hrIGF-I) on steroid production in cultured equine Leydig cells during sexual maturation. Anim.
Reprod. Sci. 89:7-19.
58
Hochereau-de Reviers, M. T., M. M. de Reviers, C. Monet-Kuntz, C. Perreau, I. Fontaine, et al.
1987. Testicular growth and hormonal parameters in the male Snell dwarf mouse. Acta
Endocrinol. (Copenh) 115:399-405.
Hyland, J. H., P. J. Wright, I. J. Clarke, R. S. Carson, D. A. Langsford, and L. B. Jeffcott. 1987.
Infusion of gonadotrophin-releasing hormone (GnRH) induces ovulation and fertile oestrus in
mares during seasonal anoestrus. J. Reprod. Fertil. Suppl. 35:211-220.
Imboden, I., F. Janett, D. Burger, M. A. Crowe, M. Hassig, and R. Thun. 2006. Influence of
immunization against GnRH on reproductive cyclicity and estrous behavior in the mare.
Theriogenology. 66(8):1866-75. 
Irvine, C. H. and S. L. Alexander. 1988. Secretion rates and short-term patterns of
gonadotrophin-releasing hormone, FSH and LH in the normal stallion in the breeding season. J.
Endocrinol. 117:197-206.
Johnson, A. L. 1986a. Induction of ovulation in anestrous mares with pulsatile administration of
gonadotropin-releasing hormone. Am. J. Vet. Res. 47:983-986.
Johnson, A. L. 1986b. Pulsatile administration of gonadotropin-releasing hormone advances
ovulation in cycling mares. Biol. Reprod. 35:1123-1130.
Johnson, A. L. 1987. Gonadotropin-releasing hormone treatment induces follicular growth and
ovulation in seasonally anestrous mares. Biol. Reprod. 36:1199-1206.
Johnson, A. L., S. E. Becker, and M. L. Roma. 1988. Effects of gonadotrophin-releasing
hormone and prostaglandin F-2 alpha on corpus luteum function and timing of the subsequent
ovulation in the mare. J. Reprod. Fertil. 83:545-551.
Johnson, C. A., D. L. Thompson, Jr., and J. A. Cartmill. 2002. Pituitary responsiveness to GnRH
in mares following deslorelin acetate implantation to hasten ovulation. J. Anim. Sci.
80:2681-2687.
Johnson, C. A., D. L. Thompson, Jr., and J. A. Cartmill. 2003. Effects of deslorelin acetate
implants in horses: single implants in stallions and steroid-treated geldings and multiple implants
in mares. J. Anim. Sci. 81:1300-1307.
Kapturczak, M. H., S. Chen, and A. Agarwal. 2005. Adeno-associated virus vector-mediated
gene delivery to the vasculature and kidney. Acta Biochim. Pol. 52:293-299.
Khan, A. S., M. L. Fiorotto, K. K. Cummings, M. A. Pope, P. A. Brown, and R. Draghia-Akli
2003a. Maternal GHRH plasmid administration changes pituitary cell lineage and improves
progeny growth of pigs. Am. J. Physiol. Endocrinol. Metab. 285:E224-E231.
Khan, A. S., M. L. Fiorotto, L. A. Hill, P. B. Malone, K. K. Cummings, D. Parghi, R. J.
Schwartz, R. G. Smith, and R. Draghia-Akli. 2002. Nonhereditary enhancement of progeny
growth. Endocrinology 143:3561-3567.
59
Khan, A. S., M. A. Pope, and R. Draghia-Akli. 2005. Highly efficient constant-current
electroporation increases in vivo plasmid expression. DNA Cell Biol. 24:810-818.
Khan A.S., L. C. Smith, R. V. Abruzzese, K. K. Cummings, M. A. Pope, P. A. Brown , and R.
Draghia-Akli. 2003b. Optimization of electroporation parameters for the intramuscular delivery
of plasmids in pigs. DNA Cell Biol. 22:807-814.
Knight, C. H., C. J. Wilde, B. J. McLeod, and W. Haresign. 1988. Exogenous GnRH induces
ovulation in seasonally anoestrous lactating goats (Capra hircus). J. Reprod. Fertil. 83:679-686.
Kulin, H. E., E. Samojlik, R. Santen, and S. Santner. 1981. The effect of growth hormone on the
Leydig cell response to chorionic gonadotrophin in boys with hypopituitarism. Clin. Endocrinol.
(Oxford) 15:463-472.
Kulinski, K. M., D. L. Thompson, Jr., E. L. Capshaw, D. D. French, and J. L. Oliver. 2002. Daily
treatment of growing foals with equine somatotropin: pathologic and endocrinologic assessments
at necropsy and residual effects in live animals. J. Anim. Sci. 80:392-400.
Largaespada, D. A. 2003. Generating and manipulating transgenic animals using transposable
elements. Reprod. Biol. Endocrinol. 1:80-90.
Lechardeur, D., K. J. Sohn, M. Haardt, P. B. Joshi, M. Monck, R. W. Graham, B. Beatty, J.
Squire, H. O'Brodovich, and G. L. Lukacs. 1999. Metabolic instability of plasmid DNA in the
cytosol: a potential barrier to gene transfer. Gene Ther. 6:482-497.
Lesbordes, J. C., T. Bordet, G. Haase, L. Castelnau-Ptakhine, S. Rouhani, H. Gilgenkrantz, and
A. Kahn. 2002. In vivo electrotransfer of the cardiotrophin-1 gene into skeletal muscle slows
down progression of motor neuron degeneration in pmn mice. Hum. Mol. Genet. 11:1615-1625.
Li, X., E. M. Eastman, R. J. Schwartz, and R. Draghia-Akli. 1999. Synthetic muscle promoters:
activities exceeding naturally occurring regulatory sequences. Nat. Biotechnol. 17:241-245.
Lopez-Alonso, C., T. Encinas, R. M. Garcia-Garcia, A. Veiga-Lopez, J. M. Ros, A. S. McNeilly,
and A. Gonzalez-Bulnes. 2005. Administration of single short-acting doses of GnRH antagonist
modifies pituitary and follicular function in sheep. Domest. Anim. Endocrinol. 29:476-487.
Lucas, M. L. and R. Heller. 2001. Immunomodulation by electrically enhanced delivery of
plasmid DNA encoding IL-12 to murine skeletal muscle. Mol. Ther. 3:47-53.
Magnan, E., L. Mazzocchi, M. Cataldi, V. Guillaume, A. Dutour, F. Dadoun, Y. Le Bouc, N.
Sauze, M. Renard, B. Conte-Devolx et al. 1995. Effect of actively immunizing sheep against
growth hormone-releasing hormone or somatostatin on spontaneous pulsatile and
neostigmine-induced growth hormone secretion. J. Endocrinol. 144:83-90.
Malinowski, K., R. A. Christensen, A. Konopka, C. G. Scanes, and H. D. Hafs. 1997. Feed
intake, body weight, body condition score, musculation, and immunocompetence in aged mares
given equine somatotropin. J. Anim. Sci. 75:755-760.
60
Malmgren, L., O. Andresen, and A. M. Dalin. 2001. Effect of GnRH immunisation on hormonal
levels, sexual behaviour, semen quality and testicular morphology in mature stallions. Equine
Vet. J. 33:75-83.
Mauras, N., S. Q. Doi, and J. R. Shapiro. 1996. Recombinant human insulin-like growth factor I,
recombinant human growth hormone, and sex steroids: effects on markers of bone turnover in
humans. J. Clin. Endocrinol. Metab. 81:2222-2226.
McKeever, K. H. and K. Malinowski. 1997. Exercise capacity in young and old mares. Am. J.
Vet. Res. 58:1468-1472.
McKeever, K. H., K. Malinowski, R. A. Christensen, and H. D. Hafs. 1998. Chronic
recombinant equine somatotropin (eST) administration does not affect aerobic capacity or
exercise performance in geriatric mares. Vet. J. 155:19-25.
Medan, M., A. H. Shalaby, S. Sharawy, G. Watanabe, and K. Taya. 2002. Induction of estrus
during the non-breeding season in Egyptian Baladi goats. J. Vet. Med. Sci. 64:83-85.
Melrose, P. A., C. Pickel, H. S. Cheramie, W. G. Henk, M. A. Littlefield-Chabaud, and D. D.
French. 1994. Distribution and morphology of immunoreactive gonadotropin-releasing hormone
(GnRH) neurons in the basal forebrain of ponies. J. Comp. Neurol. 339:269-287.
Moore, A., C. L. Chen, J. R. Davis, and I. D. Morris. 1993. Insulin-like growth factor-I mRNA
expression in the interstitial cells of the rat testis. J. Mol. Endocrinol. 11:319-324.
Mumford, E. L., E. L. Squires, K. D. Peterson, T. M. Nett, and D. J. Jasko. 1994. Effect of
various doses of a gonadotropin-releasing hormone analogue on induction of ovulation in
anestrous mares. J. Anim. Sci. 72:178-183.
Nadal, M. R., D. L. Thompson, Jr., and L. A. Kincaid. 1997. Effect of feeding and feed
deprivation on plasma concentrations of prolactin, insulin, growth hormone, and metabolites in
horses. J. Anim. Sci. 75:736-744.
Neumann, E., S. Kakorin, and K. Toensing. 1999. Fundamentals of electroporative delivery of
drugs and genes. Bioelectrochem. Bioenerg. 48:3-16.
Neuvians, T. P., I. Gashaw, A. Hasenfus, A. Hacherhacker, E. Winterhager, and R. Grobholz.
2005. Differential expression of IGF components and insulin receptor isoforms in human
seminoma versus normal testicular tissue. Neoplasia 7:446-456.
Pickett, B. W., L. C. Faulkner, G. E. Seidel, Jr., W. E. Berndtson, and J. L. Voss. 1976.
Reproductive physiology of the stallion VI. Seminal and behavioral characteristics. J. Anim. Sci.
43:617-618.
61
Porter, M. B., B. D. Cleaver, M. Peltier, G. Robinson, and D. C. Sharp. 1997a. The effect of
pulsatile gonadotropin-releasing hormone and estradiol administration on luteinizing hormone
and follicle-stimulating hormone concentrations in pituitary stalk-sectioned ovariectomized pony
mares. Domest. Anim. Endocrinol. 14:275-285.
Porter, M. B., B. D. Cleaver, M. Peltier, G. Robinson, W. W. Thatcher, and D. C. Sharp. 1997b.
Comparative study between pony mares and ewes evaluating gonadotrophic response to
administration of gonadotrophin-releasing hormone. J. Reprod. Fertil. 110:219-229.
Pruett, H. E., D. L. Thompson, Jr., J. A. Cartmill, C. C. Williams, and L. R. Gentry. 2003.
Thyrotropin releasing hormone interactions with growth hormone secretion in horses. J. Anim.
Sci. 81:2343-2351.
Rabb, M. H., D. L. Thompson, Jr., B. E. Barry, D. R. Colborn, K. E. Hehnke, and F. Garza Jr.
1990. Effects of active immunization against GnRH on LH, FSH and prolactin storage, secretion
and response to their secretagogues in pony geldings. J. Anim. Sci. 68:3322-3329.
Rahmanian, M. S., D. L. Thompson, Jr., and P. A. Melrose. 1997. Immunocytochemical
localization of prolactin and growth hormone in the equine pituitary. J. Anim. Sci.
75:3010-3018.
Ritar, A. J., W. M. Maxwell, and S. Salamon. 1984. Ovulation and LH secretion in the goat after
intravaginal progestagen sponge-PMSG treatment. J. Reprod. Fertil. 72:559-563.
Rubianes, E. and A. Menchaca. 2003. The pattern and manipulation of ovarian follicular growth
in goats. Anim. Reprod. Sci. 78:271-287.
Satoh, K., K. Ohyama, Y. Nakagomi, M. Ohta, Y. Shimura, T. Sano, H. Ishikawa, S. Amemiya,
and S. Nakazawa. 2002. Effects of growth hormone on testicular dysfunction induced by
cyclophosphamide (CP) in GH-deficient rats. Endocr. J. 49(6):611-619.
Sakurai, H., B. M. Adams, and T. E. Adams. 1992. Pattern of gonadotropin-releasing hormone
(GnRH)-like stimuli sufficient to induce follicular growth and ovulation in ewes passively
immunized against GnRH. Biol. Reprod. 47:177-184.
Sakurai, H., B. M. Adams, and T. E. Adams. 1995. Gonadotroph responsiveness in
orchidectomized sheep: IV. Effect of estradiol infusion during the breeding and anestrous
seasons. Biol. Reprod. 52:382-389.
Sharp, D. C. 1988. Transition into the breeding season: clues to the mechanisms of seasonality.
Equine Vet. J. 20:159-161.
Sharp, D. C. and W. R. Grubaugh. 1987. Use of push-pull perfusion techniques in studies of
gonadotrophin-releasing hormone secretion in mares. J. Reprod. Fertil. Suppl. 35:289-296.
62
Smith, E. P., M. E. Svoboda, J. J. van Wyk, A. L. Kierszenbaum, and L. L. Tres. 1987. Partial
characterization of a somatomedin-like peptide from the medium of cultured rat Sertoli cells.
Endocrinology 120:186-193.
Smith, L. A., D. L. Thompson, Jr., D. D. French, and B. S. Leise. 1999. Effects of recombinant
equine somatotropin on wound healing, carbohydrate and lipid metabolism, and endogenous
somatotropin responses to secretagogues in geldings. J. Anim. Sci. 77:1815-1822.
Smith, L. C. and J. L. Nordstrom. 2000. Advances in plasmid gene delivery and expression in
skeletal muscle. Curr. Opin. Mol. Ther. 2:150-154.
Spiteri-Grech, J. and E. Nieschlag. 1992. The role of growth hormone and insulin-like growth
factor I in the regulation of male reproductive function. Horm. Res. 38 Suppl 1:22-27.
Stewart, F., J. A. Goode, and W. R. Allen. 1993. Growth hormone secretion in the horse: unusual
pattern at birth and pulsatile secretion through to maturity. J. Endocrinol. 138:81-89.
Sticker, L. S., D. L. Thompson, Jr., L. D. Bunting, J. M. Fernandez, C. L. DePew, and M. R.
Nadal. 1995a. Feed deprivation of mares: plasma metabolite and hormonal concentrations and
responses to exercise. J. Anim. Sci. 73:3696-3704.
Sticker, L. S., D. L. Thompson, Jr., J. M. Fernandez, L. D. Bunting, and C. L. DePew. 1995b.
Dietary protein and(or) energy restriction in mares: plasma growth hormone, IGF-I, prolactin,
cortisol, and thyroid hormone responses to feeding, glucose, and epinephrine. J. Anim. Sci.
73:1424-1432.
Sticker, L. S., D. L. Thompson, Jr., and L. R. Gentry. 2001. Pituitary hormone and insulin
responses to infusion of amino acids and N-methyl-D,L-aspartate in horses. J. Anim. Sci.
79:735-744.
Storer, W. A., D. L. Thompson, Jr., and J. A. Cartmill. 2005. The effects of equine somatotropin
on pituitary and testicular function in the stallion during the nonbreeding season. J. Equine Vet.
Sci. 25:106-112.
Stout, T. A. and B. Colenbrander. 2004. Suppressing reproductive activity in horses using GnRH
vaccines, antagonists or agonists. Anim. Reprod. Sci. 82-83:633-643.
Terada, Y., H. Tanaka, T. Okado, S. Inoshita, M. Kuwahara, T. Akiba, S. Sasaki, and F.
Marumo. 2001. Efficient and ligand-dependent regulated erythropoietin production by naked dna
injection and in vivo electroporation. Am. J. Kidney Dis. 38:S50-S53.
Thompson, D. L., Jr. 2000. Immunization against GnRH in male species (comparative aspects).
Anim. Reprod. Sci. 60-61:459-469.
63
Thompson, D. L., Jr., C. L. DePew, A. Ortiz, L. S. Sticker, and M. S. Rahmanian. 1994. Growth
hormone and prolactin concentrations in plasma of horses: sex differences and the effects of
acute exercise and administration of growth hormone-releasing hormone. J. Anim. Sci.
72:2911-2918.
Thompson, D. L., Jr., R. A. Godke, and E. L. Squires. 1983a. Testosterone effects on mares
during synchronization with altrenogest: FSH, LH, estrous duration and pregnancy rate. J. Anim.
Sci. 56:678-686.
Thompson, D. L., Jr., B. W. Pickett, E. L. Squires, and T. M. Nett. 1979. Effect of testosterone
and estradiol-17β alone and in combination on LH and FSH concentrations in blood serum and
pituitary of geldings and in serum after administration of GnRH. Biol. Reprod. 21:1231-1237.
Thompson, D. L., Jr., M. S. Rahmanian, C. L. DePew, D. W. Burleigh, C. J. DeSouza, and D. R.
Colborn. 1992. Growth hormone in mares and stallions: pulsatile secretion, response to growth
hormone-releasing hormone, and effects of exercise, sexual stimulation, and pharmacological
agents. J. Anim. Sci. 70:1201-1207.
Thompson, D. L., Jr., S. I. Reville, M. P. Walker, D. J. Derrick, and H. Papkoff. 1983b.
Testosterone administration to mares during estrus: duration of estrus and diestrus and
concentrations of LH and FSH in plasma. J. Anim. Sci. 56:911-918.
Tsurumi, C., Y. Shimizu, M. Saeki, S. Kato, G. N. Demartino, C. A. Slaughter, M. Fujimuro, H.
Yokosawa, M. Yamasaki, K. B. Hendil, A. Toh-e, N. Tanahashi, and K. Tanaka. 1996. cDNA
cloning and functional analysis of the p97 subunit of the 26S proteasome, a polypeptide identical
to the type-1 tumor-necrosis-factor-receptor-associated protein-2/55.11. Eur. J. Biochem.
239:912-921.
Turkstra, J. A., F. J. van der Meer, J. Knaap, P. J. Rottier, K. J. Teerds, B. Colenbrander, and R.
H. Meloen. 2005. Effects of GnRH immunization in sexually mature pony stallions. Anim.
Reprod. Sci. 86:247-259.
Turner, J. E. and C. H. Irvine. 1991. The effect of various gonadotrophin-releasing hormone
regimens on gonadotrophins, follicular growth and ovulation in deeply anoestrous mares. J.
Reprod. Fertil. Suppl. 44:213-225.
Vance, M. L., D. L. Kaiser, W. S. Evans, R. Furlanetto, W. Vale. W, J. Rivier, and M. O.
Thorner. 1985. Pulsatile growth hormone secretion in normal man during a continuous 24-hour
infusion of human growth hormone releasing factor (1-40). Evidence for intermittent
somatostatin secretion. J. Clin. Invest. 75:1584-1590.
Vickers M., P. Casey, Z. Champion, C. Gravance, B. Breier. 1999. IGF-I treatment increases
motility and improves morphology of immature spermatozoa in the GH-deficient dwarf (dw/dw)
rat. Growth Horm. IGF Res. 9(4):236-240.
64
Weesner, G. D., B. A. Becker, and R. L. Matteri. 1997. Expression of luteinizing
hormone-releasing hormone and its receptor in porcine immune tissues. Life Sci. 61:1643-1649.
Whitley, N. C. and D. J. Jackson. 2004. An update on estrus synchronization in goats: a minor
species. J. Anim. Sci. 82 E-Suppl:E270-E276.
Wolff, J. A., R. W. Malone, P. Williams, W. Chong, G. Acsadi, A. Jani, and P. L. Felgner. 1990.
Direct gene transfer into mouse muscle in vivo. Science 247:1465-1468.
Yasui, A., K. Oda, H. Usunomiya, K. Kakudo, T. Suzuki, T. Yoshida, H. M. Park, K. Fukazawa,
and T. Muramatsu. 2001. Elevated gastrin secretion by in vivo gene electroporation in skeletal
muscle. Int. J. Mol. Med. 8:489-494.
65
VITA
William Andrew Storer, son of George and Courtney Storer, was born in Moss Bluff,
Louisiana, on April 4, 1976.  William is the oldest of four children.  He resided in Moss Bluff
until the age of 18 and attended high school at Sam Houston High.  After graduating in 1994,
William was accepted into McNeese State Univeristy in Lake Charles, Louisiana, where he
earned a bachelor of science degree in agriculture.  In August of 2000, William began working
towards a master of science degree in animal sciences at Louisiana State University; he married
Kristina Hope Barnett the following year.  In August of 2002, he began the pursuit of the
doctoral degree in animal sciences at Louisiana State University, and became the proud father of
Cameron William Storer in 2005.  After completing his doctorate, William plans to move to
Lake Charles, Louisiana, to begin teaching at McNeese State University.  
